Honey impregnated composite dressing having super absorbency and intelligent management of wound exudate and method of making same

ABSTRACT

A super absorbent, honey-dosed foam/fiber composite, gap patterned wound dressing, comprising: a patterned foam/fiber composite structure having a gap patterned side and a non-gap patterned side, wherein the patterned side includes a pattern of foam/fiber gaps disposed between foam/fiber areas dosed with honey, where the pattern of foam/fiber gaps is formed by the honey-dosed areas, such that the patterned foam/fiber composite structure includes a layer of super absorbent material located substantially adjacent to the honey-dosed areas; and wherein a wound in contact with the gap patterned side discharges an exudate which substantially collects in the individual ones of the foam/fiber gaps causing honey in the individual ones of the honey-dosed areas to be substantially dispersed throughout a wound treatment zone and a portion of the exudate that is collected in the individual ones of the foam/fiber gaps is transferred to and collected in the super absorbent material.

CROSS-REFERENCE TO A RELATED APPLICATION

This application is a continuation-in-part of U.S. patent applicationSer. No. 13/939,829, filed Jul. 11, 2013; and a continuation-in-part ofU.S. patent application Ser. No. 29/511,393, filed on Dec. 10, 2014.

FIELD OF THE INVENTION

This invention relates generally to medical grade composite dressingsand more particularly to a gap-patterned, medical grade honey bearingcomposite dressing having super absorbency and intelligent management ofwound exudate.

BACKGROUND OF THE INVENTION

Prior to the present invention, as set forth in general terms above andmore specifically below, it is known, to employ various dressing designsfor applications to wounds. See for example, U.S. Pat. No. 3,767,784 byGluck, U.S. Pat. No. 4,231,357 by Hessner, U.S. Pat. No. 4,649,909 byThompson, U.S. Pat. No. 5,086,764 by Gilman, U.S. Pat. No. 6,605,751 byGibbins, et al., U.S. Pat. No. 6,697,261 by Soerens, at al., U.S. Pat.No. 7,220,889 by Sigurjonsson, et al., U.S. Pat. No. 7,714,183 byCaskey, U.S. Patent Application Publication 2008/0027366 by De SilvaMacedo, Jr., U.S. Patent Application Publication 2011/0135726 by Munro,et al., U.S. Patent Application Publication 2014/0127283 by Watson, U.S.Patent Application Publication 2014/0142522 by Filippova, at al., andU.S. Pat. RE 42,755 E by Molan. While these various wound dressings mayhave been generally satisfactory, there is nevertheless a need for a newand improved super absorbent, honey bearing composite wound dressinghaving super absorbency with intelligent management of wound exudateswhere the honey in the honey bearing areas of the wound dressing isdelivered to a wound treatment area under force of exudates in the woundtreatment area flowing from the wound treatment area into the compositedressing and then be transferred to and collected in a super absorbentmaterial.

It is a purpose of this invention to fulfill this and other needs in theart in a manner more apparent to the skilled artisan once given thefollowing disclosure.

SUMMARY OF THE INVENTION

A first aspect of the present invention is a honey bearing compositewound dressing having super absorbency with intelligent management ofwound exudates, comprising a patterned foam/fiber composite structurehaving a gap patterned side and a non-gap patterned side, wherein thepatterned side includes a pattern of foam/fiber gaps disposed betweenfoam/fiber areas dosed with honey, where the pattern of foam/fiber gapsis formed by the honey-dosed areas, such that the patterned foam/fibercomposite structure includes a layer of super absorbent material locatedsubstantially adjacent to the honey-dosed areas; and wherein a wound incontact with the gap patterned side discharges an exudate whichsubstantially collects in the individual ones of the foam/fiber gapscausing honey in the individual ones of the honey-dosed areas to besubstantially dispersed throughout a wound treatment zone and a portionof the exudate that is collected in the individual ones of thefoam/fiber gaps is transferred to and collected in the super absorbentmaterial.

In one embodiment of the first aspect of the present invention,individual ones of the honey-dosed areas are hexagon-shaped areas.

In another embodiment of the first aspect of the present invention, thesuper absorbent material is a medical-grade, super absorbent polymer.

In another embodiment of the first aspect of the present invention, thesuper absorbent material is a medical-grade, super absorbent powder.

In yet another embodiment of the first aspect of the present invention,the wound dressing is further comprised of a bacterial barrier layerhaving a proximal side and a distal side wherein the non-gap patternedside of the patterned foam/fiber composite is located substantiallyadjacent to the proximal side of the bacterial barrier layer.

In still yet another embodiment of the first aspect of the presentinvention, the bacterial barrier layer is a medical-grade, breathablematerial which has an adhesive coating substantially applied to theproximal side.

In yet another embodiment of the first aspect of the present invention,the wound dressing has a removable liner located substantially adjacentto the distal side of the bacterial barrier material.

In another embodiment of the first aspect of the present invention, theremovable liner is medical grade, polyethylene.

In yet another embodiment of the first aspect of the present invention,the wound dressing is further comprised of a removable liner locatedsubstantially adjacent to the proximal side of the bacterial barriermaterial and substantially enclosing the patterned foam/fiber composite,wherein the removable liner is a medical grade, high densitypolyethylene.

In yet another embodiment of the first aspect of the present invention,the patterned foam/fiber composite structure has a thickness in a rangeof between 0.05 mm to about 100 mm.

In still yet another embodiment of the first aspect of the of thepresent invention, the wound dressing is further comprised of a geladhesive layer wherein the gel adhesive layer is located substantiallyadjacent to the foam/fiber composite and the proximal side of thebacterial barrier material.

In yet another embodiment of the first aspect of the present invention,the gel adhesive layer is a silicone gel adhesive.

A second aspect of the present invention is a honey bearing compositewound dressing having super absorbency with intelligent management ofwound exudates, comprising a foam/fiber layer having a gap patternedside and a non-gap patterned side, wherein the patterned side includes apattern of foam/fiber gaps disposed between foam/fiber areas dosed withhoney, where the pattern of foam/fiber gaps is formed by the honey-dosedareas; a super absorbent material layer having a proximal side and adistal side wherein the proximal side of the super absorbent material islocated adjacent to the non-gap patterned side of the foam/fiber layer;and a non-woven material layer having a proximal side and a distal sidewherein the proximal side of the non-woven layer is located adjacent tothe distal side of the super absorbent material layer.

In one embodiment of the second aspect of the present invention, thefoam/fiber layer is a medical grade, polyether polyurethane foam with apolyolefin fiber matrix.

In another embodiment of the second aspect of the present invention, thesuper absorbent material layer is a medical-grade, super absorbentpolymer.

In another embodiment of the second aspect of the present invention, thesuper absorbent material layer is a medical-grade, super absorbentpowder.

In another embodiment of the second aspect of the present invention, thefoam/fiber layer has a thickness in a range of between 0.05 mm to about100 mm.

In yet another embodiment of the second aspect of the present invention,the bacterial barrier layer is a medical-grade, breathable materialwhich has an adhesive coating substantially applied to the proximalside.

In still yet another embodiment of the second aspect of the presentinvention, the non-woven material includes a medical-grade, non-wovenmaterial.

In yet another embodiment of the second aspect of the present invention,the non-woven material includes a discontinuous hot-melt thermaladhesive coating conventionally applied to one face of the non-wovenmaterial.

In a third aspect of the present invention is a method for preparing asuper absorbent, honey-dosed foam/fiber composite, gap patterned wounddressing, comprising the steps of: placing a layer of super absorbentmaterial substantially over a layer of foam/fiber material; placing alayer of a non-woven material substantially over the layer of superabsorbent material; preparing and placing a layer of a bacterial barriermaterial substantially over the layer of non-woven material; placing acasting layer substantially over the layer of bacterial barriermaterial; heating the layers of foam/fiber, super absorbent material,non-woven material, the bacterial barrier layer, and casting layer tosubstantially join the layers of foam/fiber, super absorbent material,non-woven material, the bacterial barrier layer, and the casting layertogether; applying specific amounts of honey to the layer of foam/fibermaterial to substantially dose a portion of the layer of foam/fibermaterial with the honey; placing a liner layer substantially over theheat sealed layers of honey-dosed foam/fiber, super absorbent material,non-woven material, bacterial barrier layer, and casting liner such thatthe liner layer is substantially adjacent to the honey-dosed foam/fibermaterial; cutting the heat sealed layers of honey-dosed foam/fiber,super absorbent material, non-woven material, the bacterial barrierlayer, and casting layer, and the liner layer; placing dressing pouchlayers substantially over and under the cut, heat sealed layers ofhoney-dosed foam/fiber, super absorbent material, non-woven material,the bacterial barrier layer, and the casting layer and the liner layer;heating the dressing pouch layers to substantially join the dressingpouch layers together, thereby enclosing the cut, heat sealed layers ofhoney-dosed foam/fiber, super absorbent material, non-woven material,the bacterial barrier layer, and the casting liner and the liner layertogether; and cutting the heat sealed, dressing pouch layers enclosingthe super absorbent, honey-dosed foam/fiber composite, gap patternedwound dressing to form individual super absorbent, honey-dosedfoam/fiber composite wound dressings.

In an embodiment of the third aspect of the present invention, the stepof placing a layer of super absorbent material substantially over alayer of foam/fiber material includes the step of utilizing a superabsorbent panel as the super absorbent material.

The preferred super absorbent, honey-dosed or impregnated, gap patternedfoam/fiber wound dressing, according to various embodiments of thepresent invention, offers the following advantages: ease of use;improved dressing strength; reduced dressing weight; increasedefficiency and controlled lay down of honey; increased ability todeliver an equal measure of honey across the wound bed; increasedability to promote controlled, naturally occurring osmotic deliveryaction of the honey onto the wound bed; increased rate of absorption ofexudates while allowing honey stored within the honey-dosed orimpregnated area to flow naturally onto the wound; improved ease ofhandling of the dressing; intelligent management of exudates through thefoam/fiber composite into the super absorbent panel; the honey isdispersed faster and more evenly into the wound; dressing liners allowfor easy handling of the dressing and protect the dressing fromaccidental damage; improved odor control; and the single-sidedapplication of honey to dressing presents the honey dose to the woundface of dressing rather than wasting unused honey on the bandage side ofdressing. In fact, in many of the preferred embodiments, these factorsof improved strength, reduced weight, increased lay down efficiency,increased honey loading, increased honey delivery, increased osmoticdelivery action, increased exudate absorption ability, improved ease ofhandling, intelligent management of exudates, honey dispersion, the useof dressing liners, improved odor control, and the single-sidedapplication of honey to the dressing are optimized to an extent that isconsiderably higher than heretofore achieved in prior, known honey-basedwound dressings.

BRIEF DESCRIPTION OF DRAWINGS

The above mentioned features and steps of the invention and the mannerof attaining them will become apparent, and the invention itself will bebest understood by reference to the following description of theembodiments of the invention in conjunction with the accompanyingdrawings, wherein like characters represent like parts throughout theseveral views and in which:

FIG. 1 is a top view of a gap-patterned medical grade foam dressing,constructed according to the present invention;

FIG. 2 is a cross-sectional view of the gap-patterned medical grade foamdressing taken substantially along line 2-2 of FIG. 1;

FIG. 3 is a diagrammatic illustration of a gap-patterned medical gradefoam dressing, wherein an exudate has caused the foam gap patternedareas to swell and expand thereby dispersing the honey out of the honeydeposits in the foam;

FIG. 4 is a schematic illustration of a pouch which contains a sterile,gap-patterned medical grade foam dressing, constructed according to thepresent invention;

FIG. 5 is a top view of another gap-patterned foam dressing, constructedaccording to the present invention;

FIG. 6 is a cross-sectional view of the gap-patterned medical grade foamdressing of FIG. 5, taken substantially along line 6-6 of FIG. 5;

FIG. 7 is a diagrammatic illustration of a gap-patterned medical gradefoam dressing, wherein an exudate has caused the foam gap patternedareas to swell and expand thereby dispersing the honey out of the honeydeposits in the foam;

FIG. 8 is a diagrammatic illustration of another medical grade foamdressing, constructed according to the present invention;

FIG. 9 is a top view of a medical grade gauze dressing with gaps in thestructure of the gauze and an anti-tackiness protective layer on bothsides, which is constructed in accordance with the present invention;

FIG. 10 is a cross-sectional view of the medical grade gauze dressingtaken substantially along line 10-10 of FIG. 9;

FIG. 11 is a diagrammatic illustration of the medical grade gauzedressing of FIG. 10 with the anti-tackiness layer removed;

FIG. 12 is a diagrammatic illustration of a medical grade gauze dressingincluding a pouch in which an absorbent pad is located, which isconstructed in accordance with the present invention;

FIG. 13 is a cross-sectional view of the medical grade gauze dressingtaken substantially along line 13-13 of FIG. 12;

FIG. 14 is a schematic illustration of the construction of agap-patterned medical grade foam dressing, constructed according to thepresent invention;

FIG. 15A is a perspective view of an adherent honey-dosed, foam/fibercomposite dressing having super absorbency covered with a protectiveliner, constructed according to the present invention;

FIG. 15B is a further perspective view of the adherent honey-dosed,foam/fiber composite dressing of FIG. 15A with the protective linerspartially removed;

FIG. 15C is a perspective view of the placement of the protective,removable liners over a non-adherent super absorbent honey-dosed,foam/fiber composite dressing having super absorbency;

FIG. 15D is a perspective view of the non-adherent super absorbenthoney-dosed, foam/fiber composite dressing of FIG. 15C with theprotective liners partially removed;

FIG. 16A is a still yet a further perspective view of an adherenthoney-dosed foam/fiber composite dressing of FIGS. 15A and 15B, with theprotective removable liners being completely removed;

FIG. 16B is a still yet a further perspective view of a non-adherent,honey-dosed, foam/fiber composite dressing of FIGS. 15C and 150, withthe protective liners being completely removed;

FIG. 17 is a top view of a honey-dosed, foam/fiber compositeconstruction, forming part of the adherent honey-dosed foam/fibercomposite dressing of FIG. 16A and the non-adherent honey-dosedfoam/fiber composite dressing of FIG. 16B;

FIG. 18 is a cross-sectional view of the honey-dosed, foam/fibercomposite construction, taken substantially along line 18-18 of FIG. 17;

FIG. 19 is a top view of a honey impregnated gauze compositeconstruction, used in the construction of the present invention;

FIG. 20 is a cross-sectional view of a portion of the honey impregnatedgauze composite construction, taken substantially along line 20-20 ofFIG. 19;

FIG. 21 is a schematic, exploded, perspective view of a honey-dosed,foam/fiber composite, forming part of the adherent honey-dosed,foam/fiber composite dressing of FIGS. 15A, 15B, and 16A and thenon-adherent honey-dosed, foam/fiber composite dressing of FIGS. 15C,15D, and 16B;

FIG. 21A is a schematic, exploded, perspective view of anotherhoney-dosed, foam/fiber composite using super absorbent powder, formingpart of the adherent honey-dosed, foam/fiber composite dressing of FIGS.15A, 15B, and 16A and the non-adherent honey-dosed, foam/fiber compositedressing of FIGS. 15C, 15D, and 16B, which is constructed according tothe present invention;

FIG. 22 is a schematic, exploded, perspective view of a honeyimpregnated gauze composite, forming part of the adherenthoney-impregnated fabric wound dressing of FIGS. 26 and 27 and thenon-adherent honey-impregnated fabric wound dressing of FIG. 28, whichis used in the construction of the present invention;

FIG. 22A is a schematic, exploded, perspective view of a honeyimpregnated gauze composite, using super absorbent powder, forming partof the adherent honey-impregnated fabric wound dressing of FIGS. 26 and27 and the non-adherent honey-impregnated fabric wound dressing of FIG.28, which is used in the construction of the present invention;

FIG. 23 is an exploded, side view of the adherent honey-dosed,foam/fiber composite dressing of FIGS. 15A and 15B:

FIG. 24 is an exploded, side view of another adherent honey-dosedfoam/fiber composite dressing, which is constructed according to thepresent invention;

FIG. 25 is an exploded, side view of the non-adherent honey-dosed,foam/fiber composite dressing of FIGS. 15C and 15D;

FIG. 26 is an exploded, side view of an adherent honey impregnated,gauze composite dressing, which is constructed according to the presentinvention;

FIG. 27 is an exploded, side view of another adherent honey impregnated,gauze composite dressing, which is constructed according to the presentinvention;

FIG. 28 is an exploded, side view of a non-adherent honey impregnated,gauze composite dressing, which is constructed according to the presentinvention;

FIG. 29 is a schematic illustration of the honey-dosed foam/fibercomposite dressing of FIG. 16A, being applied to a wound, according tothe present invention;

FIG. 30 is a schematic illustration of the honey impregnated gauzecomposite dressing of FIG. 26, being applied to a wound, according tothe present invention;

FIG. 31 is a schematic illustration of the construction of ahoney-dosed, foam/fiber composite super absorbent dressing, constructedaccording to the present invention; and

FIG. 32 is a schematic illustration of the construction of a honeyimpregnated, gauze, super absorbent dressing, constructed according tothe present invention.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Referring now to the drawings and more particularly to FIGS. 1-3, thereis illustrated a gap-patterned medical grade foam dressing 50, which isconstructed in accordance with the present invention. As will beexplained hereinafter in greater detail, the dressing 50 is constructedto provide a pumping action that pulls or draws exudates from a woundinto the dressing 50 and disperses a precise dose of honey 14 from thedressing 50 throughout the wound treatment zone. The advantages of foamdressing 50 are the improved management of exudates through the foam gappatterned areas in dressing 50, the swelling of the foam gap patternedareas supports natural osmotic pump action of the honey, tackiness indressing 50 is reduced because there are gaps between the honey-dosedareas, the honey is dispersed faster and more evenly into the wound, dryedges around dressing 50 allow for easy handling of the dressing 50 andprotect the dressing from accidental damage, and the single-sidedapplication of honey to dressing 50 presents the honey dose to the woundface of dressing 50 rather than wasting unused honey on the bandage sideof dressing 50.

Considering now the gap-patterned medical grade foam dressing 50, ingreater detail with reference to FIGS. 1-3, the gap-patterned medicalgrade foam dressing 50 generally includes a flexible sheet of polyetherpolyurethane foam 4 having a non-wound contact side indicated generallyat 60 (FIG. 2) and a wound contact side indicated generally at 61 (FIG.2). The non-wound side 60 of the dressing 50 is protected with abreathable barrier 6, having a (Z) thickness of about 30 microns, asbest seen in FIG. 2. The barrier 6 is composed of a sheet of breathablepolyurethane. While barrier 6 is cosmetic, its purpose is to protect thedressing 50 from debris and liquid contamination.

Dressing 50 may also be provided with a dry picture frame edge 56 (FIGS.1 and 2) which facilitates ease of handling of the dressing 50 duringthe wound dressing application process. Foam 4 is medical grade foamthat is highly absorbent, flexible, porous and fully breathable to helpfacilitate the formation of a moist wound environment which is highlyconducive for body healing purposes.

As best seen in FIG. 2, the wound contact side 61 of the dressing 50 isprovided with a patterned plurality of foam gaps 54 interspersed with apatterned plurality of honey-dosed foam areas 52. The foam gaps 54 areformed in the foam 4 when the foam 4 is dosed with honey 14, which is animportant feature of the present invention. That is, the patterns ofhoney-dosed foam areas 52 and the patterns of non-dosed foam gaps 54cooperate with one another to create a pumping, push-pull action thatallows the dressing 50 to: 1) absorb or pull wound exudates from atreated wound area into the non-dosed foam gaps 54; and 2) to dispersesubstantially the totality of the honey 14 in the honey-dosed foam areas52 onto the treated wound area covered by the dressing 50.

While in the preferred embodiment of the present invention, thepatterned dressing 50 is illustrated as being provided with a gappedhoneycomb pattern, it should be appreciated by those skilled in the art,that any suitable gap-patterned shape can be employed, although thegapped hexagon pattern is the preferred shape. Studies on the geometryof the honeycomb pattern explain that no other shape can create morespace. Circles for instance leave spaces, and squares make smallerareas. In addition, the hexagon structure reduces the weight of dressing50.

Furthermore, the honeycomb design allows for the most efficient andcontrolled lay down of honey 14 onto the dressing 50, creating roughly300 honey-dosed areas 52 in a 10×10 cm dressing. It is calculated thateach honey-dosed area 52 will contain around 0.025 g of honey 14. Thegap-patterned foam matrix also allows for the dressing 50 to remainflexible and pliable making it easily conformable to the wound.

With respect to foam 4, foam 4 preferably is constructed of any suitablemedical grade, breathable, absorbent, flexible and porous polymericfoam, preferably, medical grade polyether polyurethane foam. It is to beunderstood that the foam should create a moist wound environment whichtriggers the bodys natural healing ability. Finally, foam 4 should besufficiently absorbent to hold deposits of honey 14 in place but not soabsorbent as to allow the deposits of honey 14 to run into the non-dosedfoam walls or foam gaps 54 disposed between the honey deposits.

As shown more clearly in FIG. 2, foam 4 should have a thickness in arange (Y) of between 0.1 mm minimum to about a maximum of 25 mm, with apreferable thickness of approximately 4 mm.

Also as shown more clearly in FIG. 2, the non-dosed foam walls or gaps54 of patterned foam dressing 50 should have a thickness in a range (W)of between 0.05 mm minimum to about a maximum of 100 mm, with apreferable thickness of 1 mm. It is to be understood that the thickness(W) should be of a range which allows sufficient absorption andswelling, while also maintaining the cosmetic look and separation ofhoney-dosed areas 52 within the gap-patterned foam dressing 50.

With respect to the honey 14 utilized to dose the foam 4, medical gradeManuka, Pasture, Ling Kahami, Portobello, Greek Pine, Yorkshire, ChileanUlmo, Chilean Rain Forrest, Australian Eucalyptus, Himalayan, ScottishHeather, Scottish Wild Flower, English Heather, English Wildflower, NewZealand Clover, Australian Clover, Cuban Comparitan, Acacia, SpanishBlossom, Tasmanian Leatherwood, Organic Honey All, New Zealand Beach,Kanuka, New Zealand Bush, New Zealand Honey Dew, Jarrah, Thyme, andKamahi honeys are all known to contain superior anti-bacterial andanti-inflammatory factors and thus are preferred honeys for the dressing50. Manuka honey also has the ability to have a rapid deodorizing effectwith patients having malodorous fumigating wounds, which could be due tothe inhibition of anaerobic bacterial growth. Finally, the high sugarlevels in honey may well result in osmotic pressure that promotesautolytic debridement and, for these reasons, Manuka honey is thepreferred honey for use in the dressing 50. The high sugar levels in thehoney result in osmotic pressure that promotes autolytic debridement.The terminology “osmotic pressure” is defined herein to mean thepressure required to maintain equilibrium of two solutions, with no netmovement between one solution (e.g., a solvent) and the other solution.The terminology “autolytic debridement” is defined herein to mean aprocess by which the body's own enzymes and moisture is used tore-hydrate, soften and liquefy hard eschar and slough (i.e., dry scaband dead tissue.

As shown in FIG. 2, the gap-patterned foam dressing 50 has a dosed honeydepth in a range (X) which is between approximately a minimum of 0.1 mmto about a maximum of 24.9 mm, with a preferred dose depth of about 3mm.

Regarding the dosage of honey 14 in dressing 50, the ratio of honeyweight to total weight of dressing 50 will vary depending upon the sizeand style of dressing 50. Preferably, the depth of the patterned foamdressing 50 is sufficient to hold a specific amount of honey 14 ofbetween 50%-75% of honey 14 to the total weight of dressing 50. Also, itis to be understood that the target dose of honey 14 for a 4 inch by 4inch (10 cm×10 cm) dressing 50 is between 0.5 g to 100 g, with thepreferable dosage being 8-10 g. However, it is to be understood thatbalance is critical in that overdosing dressing 50 with honey 14 mayresult in a functional failure of dressing 50 because the foam structure4 may become over saturated thereby decreasing the rate at whichdressing 50 absorbs exudates. It is to be understood that it is notnecessary to have a three-dimensional shape with a flat bottom. Thebottom could taper off into a point.

The majority of the honey 14 is contained within the dosed areas 52 butthe surface of the dressing 50 has a micro thin or minimal trace layer58 of honey 14, which is of such a minimal amount that the top surfaceis not sticky and is easy to handle. Moreover, the dressing 50 has beendesigned with dry edges 56 (FIGS. 1 and 2) around all four sides ofdressing 50, thereby reducing tackiness of dressing 50. This allows foreasy handling relative to placing dressing 50 on a wound once theprotective liner 20 (FIG. 2) has been removed and the dressing face isexposed. It is to be understood that tackiness of dressing 50 is reducedbecause there are gaps between the honey-dosed areas. The dosing iscontrolled, thus not saturating the dressing 50. The honey 14 is dosedinto the areas 52 thus creating optimal storage of the honey 14 withinthe honey-dosed areas 52. It is to be further understood that dry edges56 can allow extra capacity for quick ingress of exudates on higherexuding wounds. Finally, it is to be understood that dressing 50 may notinclude dry edges 56. It is to be understood that honey 14 is preventedfrom oozing off of dry edges 56 because the moisture within honey 14 isreduced once it is dosed into the foam 4.

As shown more clearly in FIGS. 2-3, foam walls or gaps 54 are designedto absorb exudates from the wound down through and into the areasbetween honey-dosed areas 52 at the rear of the dressing 50. In thismanner, areas 52 disperse the honey 14 throughout the wound treatmentzone through the naturally occurring osmotic action. This design allowsfor an even delivery of honey 14 across the wound bed.

With respect to FIG. 2, barrier 6, preferably, is any suitable,breathable barrier constructed of polyurethane film. While barrier 6 iscosmetic, the purposes of barrier 6 are to provide a barrier to stopbacterial infection from outside of the wound, to stop any honey 14 frompotentially bleeding through barrier 6, to protect the dressing 50 fromdebris or liquid contamination and to stop exudates from bleedingthrough dressing 50. Preferably, the thickness (Z) of barrier 6 isaround 30 microns. Barrier 6 is preferably, conventionally pre-coatedwith a medical grade medium tack acrylic or silicone pressure sensitiveadhesive 62. It is to be understood that barrier 6 can also be attachedto gap-patterned dressing 50 by conventional heat bonding.

Located over honey 14 in patterned dressing 50 is a conventional,peelable liner 20 which is attached to patterned dressing 50 by thinmicro or minimal trace layer 58 of honey 14.

As shown more clearly in FIG. 3, an important feature of the patterneddressing 50 is the foam walls or gaps 54 between the honey-dosed areas52. The foam walls or gaps 54 in the patterned dressing 50 permitexudates 70 (water) to pass through and between the honey-dosed areas 52and collect in foam walls or gaps 54. This enhances a naturallyoccurring osmotic pumping action by causing the foam walls or gaps 54 toswell, thereby taking up space and applying pressure to the honey-dosedareas 52. As can be seen in FIG. 3, exudates 70 cause foam walls or gaps54 to expand out which, in turn, applies pressure to the adjacenthoney-dosed areas 52. As a result, the honey 14 is dispersed out ofhoney-dosed areas 52. This provides a steady supply of honey 14throughout the wound treatment zone. This action will continue until thehoney 14 is depleted which results in substantially the completedispersion of the honey 14 from the dressing 50 throughout the woundtreatment zone.

With respect to FIG. 4, there is illustrated a complete dressing package80 that includes a pouch 82 which encloses a gap-patterned, medicalgrade foam dressing 50. Pouch 82, preferably, is constructed of anysuitable polyester and/or polyethylene material so as to provide amoisture barrier for dressing 50. Located around the perimeter of pouch82 is a conventional, peelable adhesive 84 which allows the pouch 82 tobe easily opened to remove dressing 50 but at the same time providesadequate moisture barrier properties to protect dressing 50.

The following EXAMPLE is being provided in order to more clearlydisclose the inventive concepts of the present invention.

Example

Foam is cut in order to form a 4 inch by 5 inch (10 cm by 12.5 cm) basefor the dressing. Approximately, 8-11 grams of honey are dosed into apattern of honey-dosed areas and foam walls or gaps on the dressing baseto form the dressing. The total weight of dressing (honey and foamstructure) was determined to be 17 grams. After the dressing has beenprepared, it is packed into a pouch 80 (FIG. 4) and conventionallypassed through a gamma irradiation plant, which is validated to FDA &ISO standards. The gamma rays irradiate and kill any live pathogens thatare present in any type of particulate or other form.

Experiment

In order to prove the efficacy of the present invention the followingexperimental results are provided.

The purpose of the experiment is to establish the absorption rate ofmedical foam dressings dosed with honey. To compare the relativeabsorption rates between continuous surface dosed dressings withselective gap-pattern dosed dressings where areas of the foam surfaceare free from honey.

Apparatus

-   a. Samples of foam cut to 4×4 cm-   b. Straight sided metal ring with 35 mm internal diameter-   c. Water-   d. Measuring Cylinder-   e. Timer-   f. Clean Flat Plate

Method

-   g. Place dressing sample on to flat clean plate.-   h. Place one open end of metal ring onto the dressing sample.-   i. Measure 10 ml of water using a pipette or other suitable device.-   j. Dispense contents of measuring device into the metal ring on the    dressing.-   k. Time how long it takes for the water to be fully absorbed into    the dressing.-   l. If the timing is difficult to adequately establish the absorption    rate, use more or less water.-   m. Thoroughly clean and dry the apparatus between each test.-   n. Use the same amount of water for each test.

Results

-   o. Table I below shows the results obtained with a cross section of    different samples:-   p.

TABLE I Time in Seconds Dressing Test Test Test Test Test Test Type 1 23 4 5 6 Average Plain 6.83 6.20 6.89 7.72 6.91 Control 1.5 mm 9.98 8.299.24 9.17 wall thickness 1.25 mm 8.56 11.21 8.57 8.96 7.66 8.34 8.88wall thickness 1 mm wall 11.12 11.86 10.30 11.09 thickness 0.75 mm 14.7911.49 13.09 15.29 13.67 wall thickness 0.5 mm 11.04 12.39 10.65 12.9011.75 wall thickness Fully 20.95 28.51 64.28 36.78 40.51 37.57 38.10coated

CONCLUSIONS

-   q. It appears from the above results that there is an increase in    absorption rate where there are gaps between the honey deposits.    This could be because the gaps provide a free channel for fluids to    access the storage capacity of the foam.-   r. Probably the presence of honey taking up capacity in the    dressing, which would otherwise be available for absorption of    fluids, has a proportional impact on the rate of absorption. This    was suggested by the fact that the heavier dosed samples more    quickly became saturated, with the excess fluid bleeding through the    dressing and onto the plate around. This fluid had honey dispersed    in it.-   s. The 0.75 mm and 0.5 mm wall thickness samples were not completely    clear of honey between the deposits, so the results appear to be    skewed slightly.

Referring back to the drawings and more particularly to FIG. 14, adressing construction apparatus 700 is illustrated, which apparatus 700is constructed in accordance with the present invention. The apparatus700 forms ribbons of foam dressing which are cut to a predeterminedlength and then packaged by means not shown for shipping purposes. Inthis regard, the results provide individual packages, such as a package80 for containing the foam dressing 50.

Considering now the method of constructing the foam dressing 54 ingreater detail, the apparatus 700 generally includes a first set of feedrollers indicated at 702 and 704, respectively. Feed roller 702 pullsinto a construction path (A) a ribbon of foam 4 from a spool of foam(not shown). The ribbon of foam 4 has a width dimension required for thedressing 50. Feed roller 704 pulls into another construction path (B), aribbon of barrier 6, whose width dimension corresponds to the widthdimension of the ribbon of foam 4. The A construction path and the Bconstruction path merge at the nip of a pair of laminating rollers 708and 713, respectively. In this regard, the foam 4 and barrier 6 traversealong the direction of the construction paths A and B, respectivelywherein the foam 4 and the barrier 6 are laminated together between theconventional laminating rollers 708 and 713 to create lamination 709.The laminating rollers 708 and 713 then cooperate with a pair ofupstream rollers, namely a heated form roller 716 and a drive roller718.

The heated form roller 716 is in fluid contact with a reservoir 712 ofliquid honey 14 so when the surface of roller 716 passes by thereservoir 712, the conventionally heated roller 716 withdraws apredetermined amount of honey 14 from reservoir 712. It is to beunderstood that reservoir 712 can be located at other positions inapparatus 700. The honey coated roller 716 and drive roller 718 thenengage the lamination 709 at their nip 703 which doses the foam side oflamination 709 such that a pattern of honey-dosed foam areas and apattern of gap foam areas or walls are created in foam 4. A thin microor minimal trace layer (58 in FIG. 2) of honey is deposited on thesurface of the patterned surface of the patterned dosed foam 740 as itemerges from between rollers 716 and 718, respectively.

As the gap-patterned foam 740 emerges from between the heated formroller 716 and drive roller 718, it is further pulled upstream by a feedroller 721 which helps drive a liner 20 into a nip between the driveroller 718 and the feed roller 721 so that liner 20 is applied to thewet surface of the gap-patterned foam 740 to form a liner coveredgap-patterned foam ribbon, indicated generally at 745. In this manner,liner 20 is retained on gap-patterned foam 740 by honey micro or minimaltrace layer 58 (FIG. 2).

Next, ribbon 745 is pulled upstream by a drive roller 722 and aconventional rotary tool roller 724 which cooperate for die cutting theliner covered gap-patterned foam ribbon 745 as ribbon 745 passes betweenrollers 722 and roller 724, where it emerges as the dressing 50. It isto be understood that all rollers, as mentioned herein, turn atsubstantially the same surface speed as lamination 709, which can beanywhere between 1 m/minute and 15 m/minute. As mentioned previously,the dressing 50 then passes into a packaging mechanism (not shown) whichpackages individual ones of the dressing 50 in a pouch 80 package forease of handling and radiation.

Although the preferred method of dosing foam with honey 14 to create orform a gap-patterned foam dressing 50 is illustrated by the apparatus700 (FIG. 14), it is contemplated that honey 14 may be placed withinhoney-dosed areas 52 of dressing 50 by other types of apparatus fordepositing honey, including but not limited to coating, dosing, pasting,impregnating, injecting, pouring, spraying, transferring, printing (allmethods) including lithography, stencilling, flexography, gravure,infusion, and rotogravure. It is to be understood that a honey coating(not shown) maybe conventionally imprinted upon foam dressing 50 so thatit appears to be a gap-patterned structure dosed with honey 14

Referring now to the drawings and more particularly to FIGS. 5-7 thereis shown another gap-patterned medical grade foam dressing 150, which isconstructed, in accordance with the present invention. The gap-patternedfoam dressing 150 is the reverse of foam dressing 50. That is, thedressing 150 is provided with non-honey-dosed gaps 154 having a hexagonshape such that non-honey-dosed hexagon shaped gaps 154 are interspersedwith honey-dosed areas 152. Other than the patterned shapes as mentionedherein, the foam dressing 150 is substantially similar to foam dressing50. Since foam dressings 50 and 150 are similar, it will suffice tomention that the foam dressing 150 is provided with a smaller dose ofhoney 14 since the honey 14 is dosed into smaller areas 152 than thoseof dosed area 52 in the dressing 50. Honey by weight in this embodimenttherefore is 25-50% by weight as opposed to between 50-75% by weight.Also like dressing 50, dressing 150 is provided with a micro thin orminimal trace layer 58 of honey 14 on its upper surface which is alsocovered with a protective cover 20, just as was the case with dressing50. The bottom surface of the foam 4 is further covered with abreathable barrier 6 which is adhered to the foam 4 by an adhesive 62,just as was the case with dressing 50.

As shown more clearly in FIG. 7, an important feature of the patterneddressing 150 is the foam walls or gaps 154 between the honey-dosed areas152. The foam walls or gaps 154 in the patterned dressing 150 permitexudates 70 (water) to pass through and between the honey-dosed areas152 and collect in foam walls or gaps 154. This enhances a naturallyoccurring osmotic pumping action by causing the foam walls or gaps 154to swell, thereby taking up space and applying pressure to thehoney-dosed areas 152. As can be seen in FIG. 7, exudates 70 cause foamwalls or gaps 154 to expand out which, in turn, applies pressure to theadjacent honey-dosed areas 152. As a result, the honey 14 is dispersedout of honey-dosed areas 152. This provides a steady supply of honey 14onto the wound treatment zone. This action will continue until the honey14 is dispersed inside and outside the dressing 150. As discussedearlier, the foam walls or gaps 154 of patterned foam dressing 150should have a thickness in a range of between 0.05 mm minimum to about amaximum of 100 mm, with a preferable thickness of 4 mm.

Referring now to the drawings and more particularly to FIG. 8, there isshown a honey-dosed foam dressing 800, which is constructed inaccordance with the present invention. Use of foam dressing 800 offersseveral advantages. For example, air passing through the foam regulatesmoisture levels at the wound site to further promote healing. Also,micro-holes in the foam act as air filters to keep debris andparticulates out of the wound while simultaneously letting fresh airinto the wound. Foam dressing 800 is substantially waterproof andquickly dries-out after getting wet. Also, the foam is flexible andstays in place when the body is in motion. In addition, the foammaterial is resilient, such that the foam material moves with the skin.This resiliency prevents the foam material from tearing and separatingfrom the wound site due to skin movement. Also, thicker foam dressingsprovide cushioning that make inadvertent contact or impact with thewound site less painful.

As described in more detail herein below, honey-dosed foam dressing 800comprises a substrate 820 made of an absorbent foam material. The foammaterial 820 has a predetermined weight and thickness. Honey 14 islayered on one side of the foam substrate 820. Honey 14 has apredetermined weight as a percentage of the total weight of dressing800. As with dressings 50 and 150, honey-dosed foam dressing 800 is usedas a wound dressing, wherein the honey layer contacts the wound site topromote healing of the wound when the dressing is applied.

The specific embodiment of the honey-dosed foam dressing 800 will now bedescribed. In this regard, and with reference to FIG. 8, honey-closedfoam dressing 800 is a wound dressing comprising one or two componentscombined into a single unit. One component is a foam substrate 820. Asecond component is a fiber reinforcement 822 to provide stability tothe foam substrate. The uncompressed density of foam substrate 820 isbetween 95-150 kg/m³. Foam substrate 820 is, preferably, about 3-4 mmthick. Foam 820, preferably, is constructed of medical grade plasticpolymer foam, such as polyether polyurethane foam.

Foam substrate 820 should have a thickness in a range (Y) of between 0.1mm minimum to about a maximum of 25 mm, with a preferable thickness ofapproximately 4 mm.

With respect to FIG. 8, barrier 6, preferably is any suitable,breathable barrier constructed of polyurethane which is conventionallypre-coated with a medical grade medium tack acrylic or silicone pressuresensitive adhesive 62. While barrier 6 is cosmetic, the purposes ofbarrier 6 are to provide a barrier to stop bacterial infection fromoutside of the wound, to stop any honey 14 from potentially bleedingthrough barrier 6, to protect the dressing 800 from debris or liquidcontamination and to stop exudates from bleeding through dressing 800.Preferably, the thickness of barrier 6 is around 30 microns. It is to beunderstood that barrier 6 can also be attached to gap-patterned dressing800 by conventional heat bonding.

Another component is honey 14 disposed on one side of foam substrate820, so that a honey layer 830 is created by an even disposition ofhoney 14 throughout foam substrate 820. Honey layer 839 is preferablyless than about 75% by weight of the total weight of wound dressing 800.As with wound dressings 50 and 150, foam wound dressing 800 is appliedsuch that honey layer 830 contacts the wound site to promote healing ofthe wound.

Referring now to the drawings and more particularly to FIGS. 9-10, thereis shown a honey-dosed gauze dressing 900, which is constructed inaccordance with the present invention. As described in more detailherein below, honey-dosed gauze dressing 900 comprises a material, suchas gauze, which contains gaps in the gauze. The surface of the gauze isdosed with honey, such that the honey resides within the gauze betweenthe gaps but substantially not in the gaps. As with dressings 50, 150and 800, the side of the material containing the honey is placed on thewound to promote healing of the wound. An anti-tackiness coating, sheetor protective layer may or may not cover the honey.

Honey comb gauze dressing 900 exhibits several advantages. As statedherein above, the gauze contains the honey within its structure. Thisparticular structure of the gauze holds more honey than standardhoney-dosed gauze dressings. The gaps in the gauze allow for greaterexpansion, conformity and flexibility of the dressing. Furthermore, thegaps allow for the free passage of exudate, if present, within thewound, so that this may be more quickly collected and managed by anyabsorbent materials surrounding the wound treatment zone. Also, in oneembodiment, honey-dosed gauze dressing 900 includes an anti-tackinesscoating, sheet or protective layer covering the honey for reducing therisk that the dressing will undesirably adhere to the wound site andwill provide the gauze with an anti-tackiness feeling to touch. However,the structure of the honey-dosed gauze dressing 900 can advantageouslyeliminate the need for an anti-tackiness layer covering the honey andtherefore, in another embodiment, the anti-tackiness layer is omitted.Finally, as previously discussed herein, the high sugar levels found inthe honey, result in an osmotic pressure that promotes autolyticdebridement.

Referring back to FIG. 9, honey comb gauze dressing 900 will now bedescribed. In this regard, and with reference to FIG. 9, honey combgauze dressing 900 includes a pattern of gaps 920 and surrounding fabric930. Gauze dressing 900, preferably, has a weight of approximately 300grams per meter squared.

Gauze dressing 900 is woven, knitted or structured so as to define aplurality of laterally adjacent linear shaped gaps 920 therein,illustrated with white background, as best seen in FIG. 9. Gaps 920 forma regular pattern similar to the parallel walls between the cells on ahoney comb, in this manner, honey-dosed gauze dressing 900 forms amatrix that may be considered analogous to the structure of a bee'shoney comb.

Honey 14 is disposed into gauze dressing 900 in the fabric 930 tocompletely fill the structure around the gaps 920. For clarity ofunderstanding the gauze dressing 900, the honey 14 is shown in FIGS.9-10 as unobstructed shaded areas. The honey dose 14 is used, amongother things, to reduce the risk of wound infection and to promotehealing, as with dressings 50, 150 and 800. The preferred weight ofhoney dose for this presentation is between 65-70% of the total dressingweight.

Located on either side of gauze dressing 900 is an anti-tackinesscoating, sheet or layer 940 and an additional protective cover 950 overhoney-dosed fabric 930. Anti-tackiness coating, sheet or layer 940 willreduce the risk that dressing 900 will undesirably adhere to the woundsite. In this regard, anti-tackiness layer 940 should have a lowstickiness property (i.e., low ability to retain solvents upon drying).Such an anti-tackiness layer 940 may comprise silicone oil, embossed orun-embossed polymer liners or other suitable anti-tackinesscompositions. As shown in FIG. 9, anti-tackiness layer 940 may be oneither or both sides of gauze dressing 900 and contacts the wound whenhoney-dosed dressing 900 is applied.

Referring now to the drawings and more particularly to FIG. 11, ahoney-dosed gauze dressing 1000 is illustrated. The honey-dosed gauzedressing 1000 is substantially similar to honey-dosed gauze dressing 900except, however, the structure of honey-dosed gauze dressing 1000 allowsfor the elimination of anti-tackiness layer 940 (FIG. 9), if desired.The ability to eliminate the anti-tackiness layer 940 without affectingthe functionality of honey-dosed gauze dressing 1000 is due to thesurface texture of the honey-dosed gauze dressing 1000. It is also to beunderstood that the elimination of anti-tackiness layer 940 inhoney-dosed gauze dressing 1000 may also reduce the amount of materialcomprising the dressing and, therefore, may reduce manufacturing costs.

Referring now to the drawings and more particularly to FIGS. 12-13,there is shown a honey-dosed gauze dressing 1100, which is constructedin accordance with the present invention. As described in more detailherein below, honey-dosed gauze dressing 1100, having a non-woundcontact side indicated generally at 60 (FIG. 13) and a wound contactside indicated generally at 61 (FIG. 13), comprises a material, such asgauze, which contains gaps in the gauze, in combination with anabsorbent pad located in a pouch attached to the gauze. The surface ofthe gauze is dosed with honey, such that the honey resides within thegauze around the gaps. As with dressings 50, 150, 800, 900 and 1000, theside of the material containing the honey is placed on the wound topromote healing of the wound. An anti-tackiness coating, sheet orprotective layer may or may not cover the honey.

Honey-dosed gauze dressing 1100 exhibits several advantages. As statedherein above, the gauze contains the honey within its structure. Thegaps in the gauze allow for greater conformity and flexibility of thedressing. Furthermore, the gaps allow for the free passage of exudatefrom the wound, so that this can be collected and managed by theabsorbent pad located within the pouch underneath the honey-dosed gauze.The absorbent pad contains super absorbent powder to manage high levelsof exudate, locking it within the secure pouch. The choice of thematerial for the wicking layer which forms one side of the pouch,between the honey-dosed gauze and the absorbent pad, allows a slowinitial transfer of exudate which thereby reduces the risk of painfulwound treatment often associated with the application of super absorbentdressings. Maintaining a steady rate of transfer of exudate promotes thecomplete dispersal of honey throughout the wound treatment zone. Also,honey-dosed gauze dressing 1100 includes a protective cover and apicture frame dry edge for ease of handling during application (FIG.13). Finally, as previously discussed herein, the high sugar levelsfound in the honey, result in an osmotic pressure that promotesautolytic debridement.

Referring back to FIGS. 12-13, honey-dosed gauze dressing 1100 will nowbe described. In this regard, and with reference to FIG. 13, honey-dosedgauze dressing 1100 includes the same gauze described in dressing 900above. A pouch 1120 is formed from an adhesive coated wicking layer 1130and the polyurethane barrier 6, as described more fully for dressing 50,which forms the backing to dressing 1100. Inside the pouch 1120, anabsorbent pad 1140 is located to collect and manage exudate from thewound. The wicking layer 1130 has an acrylate or thermal adhesive 1132which has the necessary wet performance properties to regulate the flowof exudate through the dressing.

Gauze 900 is woven, knitted or structured so as to define a plurality oflaterally adjacent linear shaped gaps 920 therein, illustrated withwhite background, as best seen in FIG. 9. Gaps 920 form a regularpattern similar to the parallel walls between the cells on a honey comb.In this manner, honey-dosed gauze dressing 900 forms a matrix that maybe considered analogous to the structure of a bee's honey comb.

Honey 14 is disposed into gauze 900 in the fabric 930 to completely fillthe structure apart from the gaps and the picture frame dry edge featureshown more clearly in FIG. 12. For clarity of understanding the gauzedressing 1100, the honey 14 is shown in FIG. 12 as unobstructed shadedareas. The honey dose 14 is used, among other things, to reduce the riskof wound infection and to promote healing, as with dressings 50, 150,800, 900 and 1000. The preferred weight of honey dose for thispresentation is between 45-65% of the total dressing weight. Finally, itis to be understood that dressing 1100 may not include dry edges 1150.

Located on the wound contact face 61 of dressing 1100 is ananti-tackiness coating, sheet or layer 940 and an additional protectivecover 950 over honey-dosed fabric 930. Anti-tackiness coating, sheet orlayer 940 will reduce the risk that dressing 1100 will undesirablyadhere to the wound site. In this regard, anti-tackiness layer 940should have a low stickiness property (i.e., low ability to retainsolvents upon drying). Such an anti-tackiness layer 940 may comprisesilicone oil, or other suitable anti-tackiness compositions. It is to beunderstood that, as described above for dressing 1000, theanti-tackiness layer 940 may not be included in dressing 1100 which willreduce manufacturing costs, without affecting the functionality ofdressing 1100, due to the surface texture of the gauze 900. Referringnow to the drawings and more particularly to FIGS. 15A and 15B, there isillustrated an, adherent, super absorbent, honey-dosed compositedressing 1500, which is constructed in accordance with the presentinvention. As will be explained hereinafter in greater detail, theadherent, super absorbent, honey-dosed composite dressing 1500 isconstructed to dispense a precise dose of honey to a wound treatmentarea while pulling or drawing exudates from the wound treatment area.The advantages of the adherent, super absorbent, honey-dosed compositedressing 1500 are increased ability to promote controlled, naturallyoccurring osmotic delivery action of honey into a wound bed, increasedrate of absorption of exudates while allowing honey stored within thehoney-dosed areas of the dressing to flow naturally onto the wound, theintelligent management of exudates through a foam/fiber compositeconstruction and into a super absorbency material, ease of use andhandling, improved dressing strength, reduced dressing weight, increasedefficiency and the controlled lay down of honey into a wound area.

Considering now the super absorbent, honey-dosed composite dressing 1500in greater detail, the super absorbent, honey-dosed composite dressing1500 generally includes a foam/fiber composite construction 1502 and abacterial barrier layer 1504. In order to protect the super absorbent,honey-dosed composite dressing 1500 from accidental exposure prior tobeing applied to a wound treatment area, such as wound treatment area2704, as best seem in FIG. 29, the super absorbent, honey-dosedcomposite dressing 1500 is also provided with a pair of protectiveremovable liners, such as a protective removable liner 1506 and aprotective removable liner 1508. Depending upon the size of thebacterial barrier layer 1504 relative to the foam/fiber compositeconstruction 1502, the protective removable liners 1506 and 1508 aresized to protect either both the foam/fiber composite construction 1502and the bacterial barrier layer 1504, as best seen in FIGS. 15A and 15Bto provide an adherent composite dressing 1500A (FIG. 16A), or, in thealternative, to protect only the foam/fiber composite construction 1502as best seen in FIGS. 15C and 15D to provide a non-adherent compositedressing 1500B (FIG. 16B). In this later case, the protective removableliners are identified as a protective removable liner 1506A and aprotective removable liner 1508A to distinguish their smaller sizerelative to the protective removable liners 1506 and 1508, respectively.

Considering now the bacterial barrier layer 1504 in greater detail, thebacterial barrier layer 1504 preferably, is constructed of any suitablemedical grade, breathable polyurethane. The bacterial barrier layer 1504is provided with a non-wound facing side and a wound facing side. Thenon-wound facing side is provided with a removable casting liner 2304which acts as a fluid stop preventing any exudates absorbed by thefoam/fiber composite construction 1502 from leaking out the backside ofthe adherent composite dressing 1500A. The wound facing side of thebacterial barrier layer 1504 is coated with a skin compatible adhesive1504A, as best seen in FIG. 23, to enable the bacterial barrier layer1504 to be secured to a non-wound facing surface of the foam/fibercomposite construction 1502 and to the removable protective liners 1506and 1508, respectively, in the case of the adherent composite wounddressing 1500A. The skin compatible adhesive 1504A also enables theadherent dressing 1500A to be secured to the patient at wound area, suchwound area 2704 (FIG. 29).

Considering now the protective removable liners 1506 and 1508respectively, only liners 1506 and 1508 will be described hereinafter ingreater detail as protective removable liners 1506A and 1508A areconstructed substantially the same except for size. Removable liners1506 and 1508, preferably, are constructed of medical gradepolyethylene. Also, a fold 1507 is conventionally created along one edgeof removable liner 1506 to aid in the removal of liners 1506 and 1508.

FIG. 5A illustrates the placement of the protective removable liners1506 and 1508 over a wound facing surface area of the composite dressing1500. In FIG. 15B, the protective removable liners 1506 and 1508 arebeing conventionally, partially peeled away from the super absorbent,honey-dosed composite dressing 1500 in order to expose the foam/fibercomposite construction 1502 so as to facilitate the application of superabsorbent, honey-dosed composite dressing 1500 to a wound treatmentarea, such as wound area 2704 (FIG. 29). FIG. 16A illustrates thehoney-dosed foam/fiber composite adherent dressing 1500A where theprotective removable liners are completely removed from the compositedressing 1500.

In use, the super absorbent, honey-dosed composite dressing 1500 is easyto handle as the honey bearing, foam/fiber composite construction 1502is protected from accidental and unwanted exposure by the protectiveliners 1506 and 1508. As best seen in FIGS. 15A, 15B, and 16A, as theliners 1506 and 1508 are peeled away and completely removed, thefoam/fiber composite construction 1502 is completely exposed therebyproviding a ready to use adherent dressing 1500A (FIG. 16A) which may bedirectly applied to a wound treatment area 2704, as best seen in FIG.29.

As best seen in FIGS. 15A and 15B, the foam/fiber composite construction1502, the bacterial barrier layer 1504, and removable liners 1506 and1508 are generally rectangular in shape. It should be understoodhowever, by those skilled in the art, that the foam/fiber compositeconstruction 1502, the bacterial barrier layer 1504, and removableliners 1506 and 1508 may be provided in other shapes and, in thisregard, their shapes are not limited to rectangular shapes as describedherein.

In the case of the non-adherent composite wound dressing 1500B (FIG.16B), the wound facing side of the bacterial barrier layer 1504 issecured only to the non-wound facing surface of the foam/fiber compositeconstruction 1502. As will be described in greater detail later withrespect to FIGS. 15A, 15B, 16A, 16B and 23-28, the bacterial barrierlayer 1504 and the removable liners 1506 and 1508 may be constructed tohave a surface area size which is substantially greater than the surfacearea size of the foam/fiber composite construction 1502 to provide theadherent, super absorbent, honey-dosed composite dressing 1500A, as bestseen in FIG. 16A, or in the alternative, the bacterial barrier layer1504 and the removable liners 1506A and 1508A may be constructed to havea surface area size which substantially conforms to the surface areasize of only the foam/fiber composite construction 1502 to provide thenon-adherent, super absorbent, honey-dosed composite dressing 1500B, asbest seen in FIG. 16B.

FIG. 15C illustrates the placement of the protective, removable liners1506A and 1508A over a wound facing surface area of the foam/fibercomposite construction 1502. In FIG. 15D, the protective removableliners 1506A and 1508A are being conventionally partially peeled awayfrom the non-adherent, super absorbent, honey-dosed composite dressing1500B in order to expose the foam/fiber composite construction 1502 soas to facilitate the application of the non-adherent, super absorbent,honey-dosed composite dressing 1500B to a wound treatment area, such aswound area 2704 (FIG. 29).

In use, as best seen in FIGS. 15C and 150, as the liners 1506A and 1508Aare peeled away and completely removed, the foam/fiber compositeconstruction 1502 is completely exposed thereby providing a ready to usenon-adherent, super absorbent, honey-dosed composite dressing 1500B(FIG. 16B) which may be directly applied to a wound treatment area, suchas wound area 2704 (FIG. 29).

As best seen in FIGS. 15C and 15D, the foam/fiber composite construction1502, the bacterial barrier layer 1504, and the removable liners 1506Aand 1508A are generally rectangular in shape. It should be understoodhowever, by those skilled in the art, that the foam/fiber compositeconstruction 1502, the bacterial barrier layer 1504, and the removableliners 1506A and 1508A may be provided in other shapes and, in thisregard, their shapes are not limited to rectangular shapes, as describedherein.

Considering now the foam/fiber composite construction 1502 in greaterdetail with reference to FIG. 21, the foam/fiber composite construction1502 generally includes a non-woven fabric layer 2104, a super absorbentpanel layer 2106, and an open cell, honey-dosed, foam/fiber structure1514 which is capable of being dosed or impregnated by honey, generallyindicated at 1510, as best seen in FIGS. 17 and 18. Preferably, thenon-woven fabric layer 2104 is a medical-grade, non-woven material whichhas a discontinuous hot-melt thermal adhesive coating 2102conventionally applied to one face. As will be described hereinafter ingreater detail, heat is applied by physical pressure of an electricallyheated tool within a construction process of manufacturing. This createsa thermal bond between the layers (2104, 2106, and 1514) of the superabsorbent, honey-dosed, foam/fiber composite construction 1502.

A unique aspect of the non-woven fabric layer 2104 is its wickingcapabilities. Non-woven fabric layer 2104 causes exudate to becontinuously fed from the wound to the super absorbent panel layer 2106(rather than a speed related function, which could be seen as causingdiscomfort to the patient). Preferably, non-woven fabric layer 2104 is100 mm×100 mm.

Super absorbent panel layer 2106, preferably, is constructed of aconventional medical-grade, super absorbent polymer. The capacity of thesuper absorbent polymer, preferably, is 4700%/© (e.g. 150 g/sq.m drysuper absorbent panel (SAP) to absorb 7050 g/sq.m fluid). Preferably,super absorbent panel layer 2106 is constructed in shapes ranging insize from 70 mm×70 mm to 80 mm×80 mm, depending upon the application.The weight of super absorbent panel layer 2106, preferably, is about0.735 g on a 10 cm×10 cm dressing. Ideally, super absorbent panel 2106will assist in drawing exudates away from foam/fiber structure 1514 sothat foam/fiber structure 1514 does not become saturated with exudates.In this manner, super absorbent panel 2106 allows foam/fiber structure1514 to remain very efficient in removing exudates from the wound areaof the patient while allowing foam/fiber structure 1514 to continue toprovide honey to the wound area 2704 (FIG. 29).

Preferably, the foam/fiber structure 1514 is constructed of medicalgrade polyether polyurethane foam with a polyolefin (non-absorbent)fiber matrix to create structural stability in the foam/fiber structure1514. Preferably, the foam/fiber structure 1514 is generally rectangularin shape with a preferred size of about 100 mm×100 mm. The foam/fiberstructure 1514 has a thickness in the range Y, as best seen in FIG. 18,of between about a minimum of 0.1 mm to a maximum of about 25.0 mm, witha preferable thickness of approximately 4.0 mm.

When dosed or impregnated with honey, a gap-patterned structure isformed where honey is dosed into the foam/fiber structure 1514 in ahoneycomb design pattern of honeycomb structures separated by gaps asbest seen in FIGS. 17-18. Honey 1510 is dosed to a depth of about X mm,where X is between approximately a minimum of 0.1 mm to about a maximumof 24.9 mm, with a preferred dose depth of about 3.0 mm. As describedabove, the honeycomb design allows for the most efficient and controlledlay down of honey 1510 onto the foam/fiber structure 1514, creatingroughly 300 honey-dosed or impregnated areas 1552 in a 10×10 cmfoam/fiber structure 1514. It is calculated that each honey-dosed orimpregnated area 1552 will contain around 0.025 g of honey 1510. Thegap-patterned matrix also allows for the foam/fiber structure 1514 toremain flexible and pliable making it easily conformable to the wound.

With respect to the honey 1510 utilized to impregnate or dose thefoam/fiber structure 1514, as described above, medical grade Manuka,Pasture, Ling Kahami, Portobello, Greek Pine, Yorkshire, Chilean Ulmo,Chilean Rain Forrest, Australian Eucalyptus, Himalayan, ScottishHeather, Scottish Wild Flower, English Heather, English Wildflower, NewZealand Clover, Australian Clover, Cuban Comparitan, Acacia, SpanishBlossom, Tasmanian Leatherwood, Organic Honey All, New Zealand Beach,Kanuka, New Zealand Bush, New Zealand Honey Dew, Jarrah, Thyme,Australian Jelly Bush, Leptospermum based honey and Kamahi honeys areall known to contain superior anti-bacterial and anti-inflammatoryfactors and thus are preferred honeys for the foam/fiber structure 1514.Manuka honey also has the ability to have a rapid deodorizing effectwith patients having malodorous fumigating wounds, which could be due tothe inhibition of anaerobic bacterial growth. Finally, the high sugarlevels in honey may well result in osmotic pressure that promotesautolytic debridement and, for these reasons, Manuka honey is thepreferred honey for use in the foam/fiber structure 1514. The high sugarlevels in the honey result in osmotic pressure that promotes autolyticdebridement. The terminology “osmotic pressure” is defined herein tomean the pressure required to maintain equilibrium of two solutions,with no net movement between one solution (e.g., a solvent) and theother solution. The terminology “autolytic debridement” is definedherein to mean a process by which the body's own enzymes and moisture isused to re-hydrate, soften and liquefy hard eschar and slough (i.e., dryscab and dead tissue).

As discussed above, the amount of honey 1510 in foam/fiber structure1514 and the ratio of honey weight to total weight of foam/fiberstructure 1514 will vary depending upon the size and style of foam/fiberstructure 1514. Preferably, the depth of the gap pattern in foam/fiberstructure 1514 is sufficient to hold a specific amount of honey 1510 ofbetween 50%-75% of honey 1510 to the total weight of foam/fiberstructure 1514. Also, it is to be understood that the target amount ofhoney 1510 for a 4 inch by 4 inch (10 cm×10 cm) foam/fiber structure1514 is between 0.5 g to 100 g, with the preferable amount being 8-10 g.However, it is to be understood that balance is critical in thatoverdosing foam/fiber structure 1514 with honey 1510 may result in afunctional failure of foam/fiber structure 1514 because the foam/fiberstructure 1514 may become over saturated thereby decreasing the rate atwhich foam/fiber structure 1514 absorbs exudates.

The majority of the honey 1510 is contained within the dosed orimpregnated areas 1552 (FIGS. 17 and 18) but the surface of thefoam/fiber structure 1514 has a micro thin or minimal trace layer 1558of honey 1510, which is of such a minimal amount that the top surface isnot sticky and is easy to handle. It is to be understood that tackinessof foam/fiber structure 1514 is reduced because there are gaps 1512between the honey-dosed or impregnated areas 1552. The dosing iscontrolled, thus not saturating the foam/fiber structure 1514. The honey1510 is dosed into the areas 1552 thus creating optimal storage of thehoney 1510 within the honey-dosed areas 1552.

It is to be understood that honey 1510 is prevented from oozing off ofthe edges of foam/fiber structure 1514 because the moisture within honey1510 is reduced once it is dosed into the foam/fiber structure 1514.

Considering now the honey comb patterned, foam/fiber structure 1514, ingreater detail with reference to FIGS. 17 and 18, the honey combpatterned, foam/fiber structure 1514 generally includes a non-woundcontact side indicated generally at 1560 (FIG. 18) and a wound contactside indicated generally at 1562 (FIG. 18). As best seen in FIG. 18, thewound contact side 1562 of the foam/fiber structure 1514 is providedwith a patterned plurality of gaps 1512 interspersed with a patternedplurality of honey-dosed or impregnated areas 1552. The gaps 1512 areformed in the foam/fiber structure 1514 when the foam/fiber structure1514 is dosed or impregnated with honey 1510, which is an importantfeature of the present invention. That is, the patterns of honey-dosedor impregnated areas 1552 and the patterns of non-dosed or impregnatedgaps 1512 cooperate with one another to create a pumping, push-pullaction that allows the foam/fiber structure 1514 to: 1) absorb or pullwound exudates from a treated wound area into the non-dosed orimpregnated gaps 1512; and 2) to disperse substantially the totality ofthe honey 1510 in the honey-dosed or impregnated areas 1552 onto thetreated wound area covered by the foam/fiber structure 1514.

Also, as shown more clearly in FIG. 18, the non-dosed or impregnatedwalls or gaps 1512 of honey-dosed, foam/fiber structure 1514 should havea thickness in a range (W) of between 0.05 mm minimum to about a maximumof 100 mm, with a preferable thickness of 1 mm. It is to be understoodthat the thickness (W) should be of a range which allows sufficientabsorption and swelling, while also maintaining the cosmetic look andseparation of honey-dosed or impregnated areas 1552 within thehoney-dosed or impregnated foam/fiber structure 514.

Referring now to the drawings and more particularly to FIGS. 19 and 20,there is shown a honey-dosed or impregnated gauze construction 1900,which is constructed in accordance with the present invention. Asdescribed in more detail herein below, honey-dosed or impregnated gauzeconstruction 1900 comprises a fabric material 1930, such as gauze, whichcontains gaps 1920 in the gauze 1930. The surface of the fabric 1930 isimpregnated with honey (shown as areas 1906), such that the honeyresides within the fabric 1930 between the gaps 1920 but substantiallynot in the gaps 1920. In order to promote healing of the wound 2704(FIG. 29), the side of the honey-dosed or impregnated gauze construction1900 containing the honey 1906 is placed on the wound 2704. The gauzeconstruction 1900, preferably, has a weight of approximately 300 gramsper meter squared. An anti-tackiness coating, sheet or protective layer(not shown) may or may not cover the honey.

As discussed above, honey impregnated gauze construction 1900 exhibitsseveral advantages. As stated herein above, the gauze construction 1900contains the honey within its structure. This particular structure ofthe gauze 1930 holds more honey than standard honey impregnated gauzedressings. The gaps 1920 in the gauze 1930 allow for greater expansion,conformity and flexibility of the gauze 1930. Furthermore, the gaps 1920allow for the free passage of exudate, if present, within the wound, sothat this may be more quickly collected and managed by any absorbentmaterials surrounding the wound treatment zone. Finally, as previouslydiscussed herein, the high sugar levels found in the honey, result in anosmotic pressure that promotes autolytic debridement.

It is to be understood that gauze 1930 is woven, knitted or structuredso as to define a plurality of laterally adjacent linear shaped gaps1920 therein, illustrated with white background, as best seen in FIG.20. Gaps 1920 form a regular pattern similar to the parallel wallsbetween the cells on a honey comb. In this manner, honey impregnatedgauze dressing 1900 forms a matrix that may be considered analogous tothe structure of a bee's honey comb.

Honey 1906 is impregnated, preferably, by conventional immersion bathtechniques, into fabric 1930 to completely fill the structure around thegaps 1920. For clarity of understanding the honey impregnated gauzeconstruction 1900, the honey 1906 is shown in FIG. 20 as unobstructedshaded areas. The honey 1906 is used, among other things, to reduce therisk of wound infection and to promote healing, as with dressings 50,150, 800 and 1500A, The preferred weight of honey dose for thispresentation is between 65-70% of the total dressing weight.

Considering now the super absorbent, honey impregnated gauze composite2200, in greater detail with reference to FIG. 22, the super absorbent,honey impregnated gauze composite 2200 generally includes a non-wovenfabric layer 2104, a super absorbent panel layer 2106, another non-wovenfabric layer 2104, and honey-impregnated gauze construction 1900.Non-woven fabric layers 2104 and super absorbent panel layer 2106 areconstructed in the same manner as those described with respect to FIG.21. Thermal bonding, via a hot melt thermal adhesive 2102, as describedwith respect to FIG. 21, is used to retain layers 2104, 2106, 2104, and1900 in place. Note that non-woven fabric layers 2104 have adiscontinuous hot-melt thermal adhesive coating 2102 conventionallyapplied to one face. Non-woven fabric layer 2104 also creates a barrierwithin the construction of the open weave fabric 1930 (FIG. 19) toprevent exudates (not shown) which accumulate in the super absorbentpanel layer 2106 (FIG. 22) from travelling the opposite way into thewound. In the foam/fiber composite version, the foam/fiber structure1514 performs this function, so the non-woven layer 2104 is only wickingand providing substance and structural integrity to the overallconstruction. Ideally, super absorbent panel 2106 will assist in drawingexudates away from honey-impregnated gauze construction 1900 so thathoney-impregnated gauze construction 1900 does not become saturated withexudates. In this manner, super absorbent panel 2106 allowshoney-impregnated gauze construction 1900 to remain very efficient inremoving exudates from the wound area of the patient while allowinghoney-impregnated gauze construction 1900 to continue to provide honeyto the wound area.

With respect to FIGS. 21A and 22A, in these embodiments, the superabsorbent panel 2106 of FIGS. 21 and 22 has been replaced with a superabsorbent powder layer 2106A. Preferably, the super absorbent powder isconstructed of any conventional medical-grade, super absorbent powderthat exhibits the same absorbent characteristics as those described withrespect to super absorbent panel 2106. Located on either side of superabsorbent powder layer 2106A are layers of tissue 2105. Tissue layers2105, preferably, are constructed of medical-grade, wicking tissue thatis capable of retaining the super absorbent powder layer 2106A whilealso providing wicking characteristics that prevent gel blocking andallow super absorbent powder layer 2106A to properly absorb the exudatesfrom the patient's wound.

Considering now the adherent, super absorbent, honey-dosed foam/fibercomposite dressing 1500, in greater detail with reference to FIGS. 15A,15B and 23, the adherent, super absorbent, honey-dosed foam/fibercomposite dressing 1500 generally includes a removable casting liner2304, a bacterial barrier layer 1504, a honey-dosed foam/fiber compositeconstruction 1502, and removable liners 1506 and 1508 having a fold 1507conventionally constructed substantially along an edge of liner 1506.Casting liner 2304 can be used as a backing for bacterial barrier layer1504 in order to provide structural integrity for bacterial barrierlayer 1504. Casting liner 2304, preferably, is constructed of medicalgrade polyethylene. For some dressing presentations, casting liner 2304can be left on, to provide support for bacterial barrier layer 1504which is relatively thin and floppy. Bacterial barrier layer 1504,preferably, is a breathable barrier having a thickness range of about20-30 microns. The bacterial barrier layer 1504 is composed of a sheetof breathable polyurethane. The purposes of bacterial barrier layer 1504are to provide a barrier to stop bacterial infection from outside of thewound, to stop any honey 1510 from composite construction 1502 frompotentially bleeding through bacterial barrier layer 1504, to protectthe foam/fiber structure 1514 of composite construction 1502 from debrisand liquid contamination, and to stop exudates from bleeding through thefoam/fiber structure 1514 of composite construction 1502. It is to beunderstood that bacterial barrier layer 1504 is shown in FIGS. 23 and 24as extending across the entire surface area of casting liner 2304. Inthis manner, bacterial barrier layer 1504 provides an adherent surface(skin compatible adhesive layer 1504A) that allows adherent dressing1500A to be attached to a wound area of a patient, as will be describedin greater detail later.

Preferably, removable liners 1506 and 1508 are constructed of anysuitable medical grade polyethylene. Preferably, casting layer 2304 maybe conventionally printed with arrows (not shown) and conventionallyslit at 2302 with an air knife (not shown) to cause a partial separationfrom the bacterial barrier layer 1504 on either side of the slit 2302.This is done to assist the nurse during application of the dressing, asthe dressing can be applied to the patient with the casting film 2304still attached for ease of handling purposes, after which the castingfilm 2304 is removed and discarded. Without this, once the removableliners 1506 and 1508 (FIGS. 15A and 15B) have been removed from theadhesive side, the nurse would find the dressing almost impossible tohandle and apply neatly to the patient's skin.

Referring now to the drawings, and more particularly to FIG. 24, thereis shown another adherent type of honey-dosed or honey-impregnatedcomposite wound dressing 2400 which is constructed in accordance withthe present invention. This adherent type of honey-dosed composite wounddressing 2400 is identical in construction to the previously describedadherent, honey-dosed composite wound dressing 1500 and will not bedescribed hereinafter in greater detail except for identifying thedifferences between these embodiments.

Considering now the adherent type of honey-dosed composite wounddressing 2400 in greater detail with reference to FIG. 24, the compositewound dressing 2400 utilizes a highly skin sensitive type of adhesivegel 2402 that covers over the exposed portion of skin compatibleadhesive layer 1504A. But for this difference in adhesives, the wounddressing 1500 and the wound dressing 2400 are identically constructed.

Gel layer 2402, preferably, is constructed of any suitable medical gradesilicone gel. In this embodiment, silicone gel is used because it is agentler adhesive that is particularly suited to patients with delicateor fragile skin.

Referring now to the drawings, and more particularly to FIG. 25, thereis shown the non-adherent type of honey-dosed composite wound dressing1500B (FIG. 16B). The non-adherent type honey-dosed composite wounddressing 1500B is constructed substantially the same as the adherenttype of honey-dosed wound dressing 1500A and will not be describedhereinafter in greater detail except for identifying the differencesbetween these embodiments.

Considering now the non-adherent, honey-dosed composite wound dressing1500B in greater detail with reference to FIG. 25, the composite wounddressing 1500B utilizes a smaller casting liner 2304 and smallerprotective liners 1506A and 1508A which are sized to cover only thesurface areas of the composite construction 1502. In this regard, thethin layer of adhesive 1504A provided on the bacterial barrier layer1504 is utilized to only secure the bacterial barrier layer 1504 and itsassociated casting liner 2304 to the composite construction 1502. In asimilar manner, the protective liners 1506A and 1508A are sized to coverthe wound facing side of the composite construction 1502. But for thesesizes differences, the adherent wound dressing 1500A and thenon-adherent wound dressing 1500B have identical constructions.

Referring now to the drawings, and more particularly to FIG. 26, thereis shown another adherent type of honey-dosed or honey-impregnatedfabric wound dressing 2500 which is constructed in accordance with thepresent invention. This adherent type of honey-impregnated fabric wounddressing 2500 is substantially identical in construction to thepreviously described adherent, honey-dosed composite wound dressing 1500and will not be described hereinafter in greater detail except foridentifying the differences between these embodiments.

Referring now to the drawings, and more particularly to FIG. 26, thereis shown another adherent type of honey-dosed or honey-impregnatedfabric wound dressing 2500 which is constructed in accordance with thepresent invention. This adherent type of honey-impregnated fabric wounddressing 2500 is substantially identical in construction to thepreviously described adherent, honey-dosed composite wound dressing 1500and will not be described hereinafter in greater detail except foridentifying the differences between these embodiments.

Considering now the adherent type of honey-impregnated fabric wounddressing 2500 in greater detail with reference to FIG. 26, the fabricwound dressing 2500 utilizes a gauze composite 2200 instead of acomposite construction 1502. But for this difference in composites, thewound dressing 1500 and the wound dressing 2500 are identicallyconstructed.

As will be described in greater detail later, the layers of the gauzecomposite 2200 in the super absorbent, honey impregnated fabric dressing2500A are held together by thermal bonding in the same manner asdescribed earlier relative to the foam/fiber composite construction1502. It is to be understood that bacterial barrier layer 1504 is shownin FIGS. 26 and 27 as extending across the entire surface area ofcasting liner 2304. In this manner, bacterial barrier layer 1504 withits thin of adhesive coating 1504A provides an adherent surface thatallows dressing 2500A to be attached to a wound area of a patient, aswill be described in greater detail later.

Referring now to the drawings, and more particularly to FIG. 27, thereis shown another adherent type of honey-impregnated fabric wounddressing 2600 which is constructed in accordance with the presentinvention. This adherent type of honey-impregnated fabric wound dressing2600 is identical in construction to the previously described adherent,honey-impregnated fabric wound dressing 2500 and will not be describedhereinafter in greater detail except for identifying the differencesbetween these embodiments.

Considering now the adherent type of honey-impregnated fabric wounddressing 2600 in greater detail with reference to FIG. 27, the fabricwound dressing 2600 utilizes a highly skin sensitive type of adhesivegel 2402 that covers over the exposed portion of skin compatibleadhesive layer 1504A. But for this difference in adhesives, the fabricwound dressing 2500 and the fabric wound dressing 2600 are identicallyconstructed it is to be understood that adhesive gel layer 2402 issubstantially the same as discussed with respect to FIG. 24.

Referring now to the drawings, and more particularly to FIG. 28, thereis shown the non-adherent type of honey-impregnated fabric wounddressing 2500B. The non-adherent type honey-impregnated fabric wounddressing 2500B is constructed substantially the same as the adherenttype of honey-impregnated fabric wound dressing 2500A and will not bedescribed hereinafter in greater detail except for identifying thedifferences between these embodiments.

Considering now the non-adherent honey-impregnated fabric wound dressing2500B in greater detail with reference to FIG. 28, the fabric wounddressing 2500B utilizes a smaller casting liner 2304 and smallerprotective liners 1506A and 1508A which are sized to cover only thesurface areas of the gauze composite 2200. In this regard, the thinlayer of adhesive 1504A provided on the bacterial barrier layer 1504 isutilized to only secure the bacterial barrier layer 1504 and itsassociated casting liner 2304 to the gauze composite 2200. In a similarmanner, the protective liners 1506A and 1508A are sized to cover thewound facing side of the gauze composite 2200. But for these sizesdifferences, the adherent wound dressing 2500A and the non-adherentwound dressing 2500B have identical constructions.

Considering now the application of super absorbent, honey-dosedfoam/fiber composite dressing 1500A to a patient's wound, in greaterdetail with reference to FIGS. 15A, 15B, 16A, 23 and 29, the superabsorbent, honey-dosed foam/fiber composite dressing 1500A has had itsremovable liners 1506 and 1508 (FIGS. 15A and 15B) conventionally peeledaway or removed to expose super absorbent, honey-dosed foam/fibercomposite dressing 1500A having a backing that includes casting liner2304 and bacterial barrier layer 1504. The super absorbent, honey-dosedfoam/fiber composite dressing 1500A is then placed over the wound area2704 of the patient 2702. The thin adhesive layer 1504A (FIG. 23)secures the dressing 1500A to the skin of the patient at about the woundarea 2704. It is to be understood that the difference between dressing1500 and dressing 1500A is that removable liners 1506 and 1508 (or 1506Aand 1508A) have been completely peeled away from composite construction1502 in dressing 1500 in order to expose composite construction 1502 ofdressing 1500A. It should also be understood that the use of thehoney-dosed foam/fiber composition dressing 1500B is similar to the useof dressing 1500A except that a conventional, external adhesive tape(not shown) is needed to secure the dressing 1500B to the skin of thepatient at about the wound area 2704.

Considering now the application to FIGS. 15A, 15B, 16A and 29, the superabsorbent, honey-dosed foam/fiber composite dressing 1500 has had itsremovable liners (1506 and 1508 in FIGS. 15A and 15B or 1506A and 1506Ain FIGS. 15C, 15D, 166 and 25) conventionally peeled away or removed toexpose super absorbent, honey-dosed foam/fiber composite dressing 1500A.The super absorbent, honey-dosed foam/fiber composite dressing 1500A isthen placed over the wound area 2704 of the patient 2702. It is to beunderstood that the difference between dressing 1500 and dressing 1500Ais that removable liners 1506 and 1508 (or 1506A and 1508A) have beencompletely peeled away from composite construction 1502 in dressing 1500in order to expose composite construction 1502 of dressing 1500A.

As discussed above, in this manner, dressing 1500A is constructed toprovide super absorbency by pulling or drawing exudates from wound area2704 into the dressing 1500A through the use of a super absorbent panel(or super absorbent powder, as described with respect to FIG. 21A) anddispersing a precise amount of honey 1510 from the dressing 1500Athroughout the treatment zone of wound 2704. In particular, the patternsof honey-dosed composite areas 1552 and the patterns of non-dosed gaps1512, as best seen in FIGS. 17 and 18, cooperate with one another tocreate a pumping, push-pull action that allows the dressing 1500A to: 1)absorb or pull wound exudates from a treated wound area 2704 into thenon-dosed gaps 1512; and 2) to disperse substantially the totality ofthe honey 1510 in the honey-dosed areas 1552 onto the treated wound area2704 covered by dressing 1500A.

Considering now the application of super absorbent, honey impregnatedfabric dressing 2500A to a patient's wound, in greater detail withreference to FIGS. 20 and 30, the super absorbent, honey impregnatedfabric dressing 2500 first has its removable liners 1506 and 1508conventionally peeled away or removed, as discussed above with referenceto FIG. 29, in order to create super absorbent, honey impregnated fabricdressing 2500A having a backing that includes casting liner 2304 andbacterial barrier layer 1504. The super absorbent, honey impregnatedfabric dressing 2500A is then placed over the wound area 2704 of thepatient 2702. It is to be understood that the difference betweendressing 2500 and dressing 2500A is that removable liners 1506 and 1508have been completely peeled away from honey impregnated fabric composite2200 in dressing 2500 in order to expose honey impregnated fabriccomposite 2200 of dressing 2500A.

As discussed above, in this manner, dressing 2500A is constructed toprovide super absorbency by pulling or drawing exudates from wound area2704 into the dressing 2500A through the use of a super absorbent paneland dispersing a precise amount of honey 1906 from the dressing 2500Athroughout the treatment zone of wound 2704. As discussed above,dressing 2500A holds more honey 1906 than standard honey impregnatedgauze dressings. The gaps 1920 in the gauze 1930 allow for greaterexpansion, conformity and flexibility of the dressing 2500A.Furthermore, the gaps 1920 allow for the free passage of exudate, ifpresent, within the wound 2704, so that this may be more quicklycollected and managed by any absorbent materials surrounding the woundtreatment zone. Finally, as previously discussed herein, the high sugarlevels found in the honey, result in an osmotic pressure that promotesautolytic debridement.

As discussed above, in this manner, dressing 2500A can also beconstructed to provide super absorbency by pulling or drawing exudatesfrom wound area 2704 into the dressing 2500A through the use of a superabsorbent powder, as described with respect to FIG. 22A and dispersing aprecise amount of honey 1906 from the dressing 2500A throughout thetreatment zone of wound 2704. As discussed above, dressing 2500A holdsmore honey 1906 than standard honey impregnated gauze dressings. Thegaps 1920 in the gauze 1930 allow for greater expansion, conformity andflexibility of the dressing 2500A. Furthermore, the gaps 1920 allow forthe free passage of exudate, if present, within the wound 2704, so thatthis may be more quickly collected and managed by any absorbentmaterials surrounding the wound treatment zone. Finally, as previouslydiscussed herein, the high sugar levels found in the honey, result in anosmotic pressure that promotes autolytic debridement.

Referring the drawings and more particularly to FIG. 31, a dressingconstruction apparatus 2900 is illustrated, which apparatus 2900 isconstructed in accordance with the present invention. The apparatus 2900forms ribbons of super absorbent, honey-dosed foam/fiber dressings whichare cut to a predetermined length and then packaged by means (not shown)for shipping purposes. In this regard, the results provide individuallypackaged, super absorbent honey-dosed foam/fiber dressings 2926.

Considering now the method of constructing the individually packaged,super absorbent, honey-dosed foam/fiber dressings 2926 in greaterdetail, the apparatus 2900 generally includes a first set of feedrollers indicated at 2902 and 2904, respectively. Feed roller 2902 pullsinto a construction path (A) cut pieces or portions of super absorbentpanel material 2106 (or super absorbent powder 2106A, as described withrespect to FIG. 21A) from a spool of super absorbent panel material (orsuper absorbent powder material). The pieces of super absorbent panelmaterial 2106 (or super absorbent powder 2106A) have a width dimensionrequired for the dressing 1500. Feed roller 2904 pulls into anotherconstruction path (B), a ribbon of foam/fiber composite structurematerial 1514, whose width dimension is larger than the width dimensionof the pieces of super absorbent panel material 2106 (or super absorbentpowder 2106A). The A construction path and the B construction path mergeat a nip 2905 and traverse along the direction of arrow C.

Feed roller 2906 pulls into a construction path (D) a ribbon ofnon-woven fabric 2104 from a spool of non-woven fabric such that theribbon of non-woven fabric 2104 is placed over the pieces of superabsorbent panel material 2106 (or super absorbent powder 2106A) andfoam/fiber structure material 1514 such that the ribbon of non-wovenfabric 2104 is placed directly over the pieces of super absorbent panelmaterial 2106 (or super absorbent powder 2106A). The ribbon of non-wovenfabric 2104 has a width dimension required for the dressing 1500. The Cconstruction path and the D construction path merge at a nip 2907 andtraverse along the direction of arrow C.

Feed roller 2908 pulls into a construction path (E) a ribbon ofbacterial barrier film 1504 and casting liner 2304 from a spool ofbacterial barrier film and casting liner such that the ribbon ofbacterial barrier film 1504 and casting liner 2304 is placed over theribbon of pieces of super absorbent panel material 2106 (or superabsorbent powder 2106A), foam/fiber structure material 1514, andnon-woven fabric 2104 such that the ribbon of bacterial barrier film1504 and casting liner 2304 is placed directly over the ribbon ofnon-woven fabric 2104. The ribbon of bacterial barrier film 1504 andcasting liner 2304 has a width dimension required for the dressing 1500.It is to be understood that the width of bacterial barrier film 1504 andcasting liner 2304 can vary depending upon whether it is desired tocover the entire surface area of dressing 1500 or just the surface areaof foam/fiber structure material 1514, as discussed above with respectto FIGS. 23-25. The C construction path and the E construction pathmerge at a nip 2909 and traverse along the direction of arrow C.

A heated platen 2910 is in close proximity with the ribbon of pieces ofsuper absorbent panel material 2106 (or super absorbent powder 2106A),foam/fiber structure material 1514, non-woven fabric 2104, bacterialbarrier film 1504, and casting liner 2304. The heat from platen 2910creates thermal bonding which causes the ribbon of pieces of superabsorbent panel material 2106 (or super absorbent powder 2106A),foam/fiber structure material 1514, non-woven fabric 2104, bacterialbarrier film 1504, and casting liner 2304 to become thermally bondedtogether.

After the ribbon of pieces of super absorbent panel material 2106 forsuper absorbent powder 2106A), foam/fiber structure material 1514,non-woven fabric 2104, bacterial barrier film 1504, and casting liner2304 are thermally bonded together, honey (not shown) is applied to theribbon of pieces super absorbent panel material 2106 (or super absorbentpowder 2106A), foam/fiber structure material 1514, non-woven fabric2104, bacterial barrier film 1504, and casting liner 2304 by honeyapplicator 2912. In particular, honey is dosed in foam/fiber structurematerial 1514, such that the side of foam/fiber structure material 1514which faces away from the pieces of super absorbent panel material 2106for super absorbent powder 2106A) is partially dosed with honey, asdescribed earlier.

Feed roller 2914 pulls into a construction path (G) a ribbon of highdensity polyethylene liners 1506, 1508 from a spool of high densitypolyethylene liners such that the ribbon of high density polyethyleneliners 1506, 1508 is placed over the heat sealed ribbon of pieces ofsuper absorbent panel material 2106 (or super absorbent powder 2106A),honey-dosed, foam/fiber structure material 1514, non-woven fabric 2104,bacterial barrier layer 1504, and casting liner 2304, such that theribbon of polyethylene liners 1506, 1508 is placed directly over theribbon of honey-dosed, foam/fiber structure material 1514. The ribbon ofpolyethylene liners 1506, 1508 has a width dimension required for thedressing 1500. Also, fold 1507, as shown in FIGS. 23-25 isconventionally constructed at this location. The C construction path andthe G construction path merge at a nip 2915 and traverse along thedirection of arrow C.

Next, the heat sealed ribbon of pieces of super absorbent panel material2106 (or super absorbent powder 2106A), honey-dosed, foam/fiberstructure material 1514, non-woven fabric 2104, bacterial barrier 1504,and casting liner 2304, and polyethylene liners 1506, 1508 isconventionally cut by cutter 2916 to create super absorbent, honey-dosedfoam/fiber dressing 1500.

After super absorbent, honey-dosed foam/fiber dressings 1500 arecreated, feed rollers 2918 pull into construction paths (H and I)ribbons of pouch film 2919 from spools of pouch film such that theribbons of pouch film 2919 are placed over and under the superabsorbent, honey-dosed foam/fiber dressings 1500. Preferably, pouch film2919 is constructed of any suitable heat sealable, medical gradepolymeric film. The C construction path and the H and I constructionpaths merge at a nip 2920 and traverse along the direction of arrow C.

A heated platen 2922 is in close proximity with the ribbons of pouchfilm 2919 and super absorbent, honey-dosed foam/fiber dressings 1500.The heat from platen 2922 creates thermal bonding which causes theribbons of pouch film 2919 to become thermally bonded together therebyenclosing the super absorbent, honey-dosed foam/fiber dressings 1500.

The heat sealed ribbon of pouch film 2919 and super absorbent,honey-dosed foam/fiber dressings 1500 is conventionally cut by cutter2924 to create individually packaged, super absorbent, honey-dosedfoam/fiber dressing packages 2926. Once this final cut is completed,super absorbent, honey-dosed foam/fiber dressing packages 2926 passthrough a conventional metal detector and inspection protocol. Finally,after the metal detector and inspection protocol are completed, packages2926 are packed and conventionally gamma irradiated for final release.

Considering now the method of constructing the individually packaged,super absorbent, honey impregnated gauze dressings 3026 in greaterdetail, the apparatus 3000 generally includes a first set of feedrollers indicated at 3002 and 3004, respectively. Feed roller 3002 pullsinto a construction path (A) a ribbon of non-woven fabric 2104 from aspool of non-woven fabric. The ribbon of non-woven fabric 2104 has awidth dimension required for the dressing 2500. Feed roller 3004 pullsinto another construction path (B), a ribbon of gauze material 1930,whose width dimension corresponds to the width dimension of the ribbonof non-woven fabric 2104. The A construction path and the B constructionpath merge at a nip 3005 and traverse along the direction of arrow C.

Feed roller 3006 pulls into a construction path (D) a ribbon of piecesor portions of super absorbent panel material 2106 (or super absorbentpowder 2106A) from a spool of super absorbent panel material (or superabsorbent powder material) such that the cut pieces of super absorbentpanel material 2106 (or super absorbent powder 2106A) are placed overthe ribbon of non-woven fabric 2104 and gauze material 1930 such thatthe pieces of super absorbent panel material 2106 (or super absorbentpowder 2106A) are placed directly over the ribbon of non-woven fabric2104. The pieces of super absorbent panel material 2106 (or superabsorbent powder 2106A) have a width dimension required for the dressing2500. The C construction path and the D construction path merge at a nip3008 and traverse along the direction of arrow C.

Feed roller 3009 pulls into a construction path (E) a second ribbon ofnon-woven fabric 2104 from a second spool of non-woven fabric such thatthe second ribbon of non-woven fabric 2104 is placed over the ribbon ofnon-woven fabric 2104, gauze material 1930, and pieces of superabsorbent panel material 2106 (or super absorbent powder 2106A) suchthat the second ribbon of non-woven fabric 2104 is placed directly overthe pieces of super absorbent panel material 2106 (or super absorbentpowder 2106A). The second ribbon of non-woven fabric 2104 has a widthdimension required for the dressing 2500. The C construction path andthe E construction path merge at a nip 3010 and traverse along thedirection of arrow C.

Feed roller 3011 pulls into a construction path (F) a ribbon ofbacterial barrier film 1504 and casting liner 2304 from a spool ofbacterial barrier film and casting liner such that the ribbon ofbacterial barrier film 1504 and casting liner 2304 is placed over theribbon of non-woven fabric 2104, gauze material 1930, pieces of superabsorbent panel material 2106 for super absorbent powder 2106A), and thenon-woven fabric 2104 such that the ribbon of bacterial barrier film1504 and casting liner 2304 is placed directly over the second ribbon ofnon-woven fabric 2104. The ribbon of bacterial barrier film 1504 andcasting liner 2304 has a width dimension required for the dressing 2500.The C construction path and the F construction path merge at a nip 3012and traverse along the direction of arrow C.

A heated platen 3014 is in close proximity with the ribbon of non-wovenfabric 2104, gauze material 1930, pieces of super absorbent panelmaterial 2106 (or super absorbent powder 2106A), the non-woven fabric2104, bacterial barrier film 1504, and casting liner 2304. The heat fromplaten 3014 creates thermal bonding which causes the ribbon of non-wovenfabric 2104, gauze material 1930, pieces of super absorbent panelmaterial 2106 for super absorbent powder 2106A), non-woven fabric 2104,bacterial barrier film 1504, and casting liner 2304 to become thermallybonded together.

After the ribbon of non-woven fabric 2104, gauze material 1930, piecesof super absorbent panel material 2106 (or super absorbent powder2106A), non-woven fabric 2104, bacterial barrier film 1504, and castingliner 2304 are thermally bonded together, honey is applied to the ribbonof non-woven fabric 2104, gauze material 1930, super absorbent panelmaterial 2106 (or super absorbent powder 2106A), non-woven fabric 2104,bacterial barrier film 1504, and casting liner 2304 by honey applicator3016, In particular, honey (not shown) is impregnated into gauzematerial 1930, such that the side of gauze material 1930 which facesaway from the first ribbon of non-woven fabric 2104 is impregnated withhoney, as described earlier.

Feed roller 3018 pulls into a construction path (H) a ribbon of highdensity polyethylene liners 1506, 1508 from a spool of high densitypolyethylene liners such that the ribbon of high density polyethyleneliners 1506, 1508 is placed over the heat sealed ribbon of non-wovenfabric 2104, honey impregnated gauze material 1930, super absorbentpanel material 2106 (or super absorbent powder 2106A), non-woven fabric2104, bacterial barrier film 1504, and casting liner 2304, such that theribbon of high density polyethylene liners 1506, 1508 is placed directlyover the ribbon of honey impregnated gauze material 1930, The ribbon ofhigh density polyethylene liners 1506, 1508 has a width dimensionrequired for the dressing 2500. Also, the fold described with respect toFIGS. 26-28 is constructed at this location. The C construction path andthe H construction path merge at a nip 3017 and traverse along thedirection of arrow C.

Next, the heat sealed ribbon of non-woven fabric 2104, honey impregnatedgauze material 1930, super absorbent panel material 2106 (or superabsorbent powder 2106A), non-woven fabric 2104, bacterial barrier layer1504, and casting liner 2304 and high density polyethylene liners 1506,1508 having fold 1507 is conventionally cut by cutter 3019 to createsuper absorbent, honey impregnated fabric dressing 2500.

After super absorbent, honey impregnated fabric dressings 2500 arecreated, feed rollers 3020 pull into construction paths (i and J)ribbons of pouch film 2919 from spools of pouch film such that theribbons of pouch film 2919 are placed over and under the superabsorbent, honey impregnated fabric dressings 2500. Preferably, pouchfilm 2919 is constructed of any suitable heat sealable, medical gradepolymeric film. The C construction path and the I and J constructionpaths merge at a nip 3021 and traverse along the direction of arrow C.

A heated platen 3022 is in close proximity with the ribbon of pouch film2919 and super absorbent, honey impregnated fabric dressings 2500. Theheat from platen 3022 creates thermal bonding which causes the ribbonsof pouch films 2919 to become thermally bonded together therebyenclosing the super absorbent, honey impregnated fabric dressings 2500.

The heat sealed ribbon of pouch film 2919 and super absorbent, honeyimpregnated fabric dressings 2500 is conventionally cut by cutter 3024to create individually packaged, super absorbent, honey impregnatedfabric dressing packages 3026. Once this final cut is completed, superabsorbent, honey impregnated fabric packages 3026 pass through aconventional metal detector and inspection protocol. Finally, after themetal detector and inspection protocol are completed, packages 3026 arepacked and conventionally gamma irradiated for final release.

The preceding merely illustrates the principles of the invention. Itwill thus be appreciated that those skilled in the art will be able todevise various arrangements which, although not explicitly described orshown herein, embody the principles of the invention and are includedwithin its spirit and scope. Furthermore, all examples and conditionallanguage recited herein are principally intended expressly to be onlyfor pedagogical purposes and to aid the reader in understanding theprinciples of the invention and the concepts contributed by theinventors to furthering the art, and are to be construed as beingwithout limitation to such specifically recited examples and conditions.Moreover, all statements herein reciting principles, aspects, andembodiments of the invention, as well as specific examples thereof, areintended to encompass both structural and functional equivalentsthereof. Additionally, it is intended that such equivalents include bothcurrently known equivalents and equivalents developed in the future,i.e., any elements developed that perform the same function, regardlessof structure.

This description of the exemplary embodiments is intended to be read inconnection with the figures of the accompanying drawing, which are to beconsidered part of the entire written description. In the description,relative terms such as “lower,” “upper,” “horizontal,” “vertical,”“above,” “below,” “up,” “down,” “top” and “bottom” as well asderivatives thereof (e.g., “horizontally,” “downwardly,” “upwardly,”etc.) should be construed to refer to the orientation as then describedor as shown in the drawing under discussion. These relative terms arefor convenience of description and do not require that the apparatus beconstructed or operated in a particular orientation. Terms concerningattachments, coupling and the like, such as “connected” and“interconnected,” refer to a relationship wherein structures are securedor attached to one another either directly or indirectly throughintervening structures, as well as both movable or rigid attachments orrelationships, unless expressly described otherwise.

All patents, publications, scientific articles, web sites, and otherdocuments and materials referenced or mentioned herein are indicative ofthe levels of skill of those skilled in the art to which the inventionpertains, and each such referenced document and material is herebyincorporated by reference to the same extent as if it had beenincorporated by reference in its entirety individually or set forthherein in its entirety. Applicants reserve the right to physicallyincorporate into this specification any and all materials andinformation from any such patents, publications, scientific articles,web sites, electronically available information, and other referencedmaterials or documents to the extent such incorporated materials andinformation are not inconsistent with the description herein.

The written description portion of this patent includes all claims.Furthermore, all claims, including all original claims as well as allclaims from any and all priority documents, are hereby incorporated byreference in their entirety into the written description portion of thespecification, and Applicant(s) reserve the right to physicallyincorporate into the written description or any other portion of theapplication, any and all such claims, Thus, for example, under nocircumstances may the patent be interpreted as allegedly not providing awritten description for a claim on the assertion that the precisewording of the claim is not set forth in haec verba in writtendescription portion of the patent.

The claims will be interpreted according to law. However, andnotwithstanding the alleged or perceived ease or difficulty ofinterpreting any claim or portion thereof, under no circumstances mayany adjustment or amendment of a claim or any portion thereof duringprosecution of the application or applications leading to this patent beinterpreted as having forfeited any right to any and all equivalentsthereof that do not form a part of the prior art.

All of the features disclosed in this specification may be combined inany combination. Thus, unless expressly stated otherwise, each featuredisclosed is only an example of a generic series of equivalent orsimilar features.

It is to be understood that while the invention has been described inconjunction with the detailed description thereof, the foregoingdescription is intended to illustrate and not limit the scope of theinvention, which is defined by the scope of the appended claims. Thus,from the foregoing, it will be appreciated that, although specificembodiments of the invention have been described herein for the purposeof illustration, various modifications may be made without deviatingfrom the spirit and scope of the invention. Other aspects, advantages,and modifications are within the scope of the following claims and thepresent invention is not limited except as by the appended claims.

The specific methods and compositions described herein arerepresentative of preferred embodiments and are exemplary and notintended as limitations on the scope of the invention. Other objects,aspects, and embodiments will occur to those skilled in the art uponconsideration of this specification, and are encompassed within thespirit of the invention as defined by the scope of the claims. It willbe readily apparent to one skilled in the art that varying substitutionsand modifications may be made to the invention disclosed herein withoutdeparting from the scope and spirit of the invention. The inventionillustratively described herein suitably may be practiced in the absenceof any element or elements, or limitation or limitations, which is notspecifically disclosed herein as essential. Thus, for example, in eachinstance herein, in embodiments or examples of the present invention,the terms “comprising”, “including”, “containing”, etc. are to be readexpansively and without limitation. The methods and processesillustratively described herein suitably may be practiced in differingorders of steps, and that they are not necessarily restricted to theorders of steps indicated herein or in the claims.

The terms and expressions that have been employed are used as terms ofdescription and not of limitation, and there is no intent in the use ofsuch terms and expressions to exclude any equivalent of the featuresshown and described or portions thereof, but it is recognized thatvarious modifications are possible within the scope of the invention asclaimed. Thus, it will be understood that although the present inventionhas been specifically disclosed by various embodiments and/or preferredembodiments and optional features, any and all modifications andvariations of the concepts herein disclosed that may be resorted to bythose skilled in the art are considered to be within the scope of thisinvention as defined by the appended claims.

The invention has been described broadly and generically herein. Each ofthe narrower species and sub-generic groupings falling within thegeneric disclosure also form part of the invention. This includes thegeneric description of the invention with a proviso or negativelimitation removing any subject matter from the genus, regardless ofwhether or not the excised material is specifically recited herein.

It is also to be understood that as used herein and in the appendedclaims, the singular forms “a,” “an,” and “the” include plural referenceunless the context clearly dictates otherwise, the term “X and/or Y”means “X” or “Y” or both “X” and “Y”, and the letter “s” following anoun designates both the plural and singular forms of that noun. Inaddition, where features or aspects of the invention are described interms of Markush groups, it is intended and those skilled in the artwill recognize, that the invention embraces and is also therebydescribed in terms of any individual member or subgroup of members ofthe Markush group.

Other embodiments are within the following claims. There ore the patentmay not be interpreted to be limited to the specific examples orembodiments or methods specifically and/or expressly disclosed herein.Under no circumstances may the patent be interpreted to be limited byany statement made by any Examiner or any other official or employee ofthe Patent and Trademark Office unless such statement is specificallyand without qualification or reservation expressly adopted in aresponsive writing by Applicants.

Although the invention has been described in terms of exemplaryembodiments, it is not limited thereto. Rather, the appended claimsshould be construed broadly, to include other variants and embodimentsof the invention, which may be made by those skilled in the art withoutdeparting from the scope and range of equivalents of the invention.

Other modifications and implementations will occur to those skilled inthe art without departing from the spirit and the scope of the inventionas claimed. Accordingly, the description hereinabove is not intended tolimit the invention, except as indicated in the appended claims.

Therefore, provided herein are a new and improved honey impregnated,patterned foam dressing and a novel method of using the honeyimpregnated, patterned foam dressing. The preferred honey impregnated,patterned foam dressing, according to various embodiments of the presentinvention, offers the following advantages: ease of use; improveddressing strength; reduced dressing weight; increased efficiency andcontrolled lay down of honey; increased ability to deliver an equalmeasure of honey across the wound bed; increased ability to promotecontrolled, naturally occurring osmotic delivery action of the honeyonto the wound bed; increased rate of absorption of exudates whileallowing honey stored within the honey-dosed area to flow naturally ontothe wound; improved ease of handling of the dressing; intelligentmanagement of exudates through the foam/fiber composite into the superabsorbent panel; the honey is dispersed faster and more evenly into thewound; dressing liners allow for easy handling of the dressing andprotect dressing from accidental damage; improved odor control, and thesingle-sided application of honey to dressing presents the honey dose tothe wound face of dressing rather than wasting unused honey on thebandage side of dressing. In fact, in many of the preferred embodiments,these factors of improved strength, reduced weight, increased lay downefficiency, increased honey loading, increased honey delivery, increasedosmotic delivery action, increased exudate absorption ability, improvedease of handling, intelligent management of exudates, honey dispersion;the use of dressing liners, odor control, and the single-sidedapplication of honey to the dressing are optimized to an extent that isconsiderably higher than heretofore achieved in prior, known honey-basedwound dressings.

We claim:
 1. A super absorbent, honey-dosed foam/fiber composite, gappatterned wound dressing, comprising: a patterned foam/fiber compositestructure having a gap patterned side and a non-gap patterned side,wherein the patterned side includes a pattern of foam/fiber gapsdisposed between foam/fiber areas dosed with honey, where the pattern offoam/fiber gaps is formed by the honey-dosed areas, such that thepatterned foam/fiber composite structure includes a layer of superabsorbent material located substantially adjacent to the honey-dosedareas; and wherein a wound in contact with the gap patterned sidedischarges an exudate which substantially collects in the individualones of the foam/fiber gaps causing honey in the individual ones of thehoney-dosed areas to be substantially dispersed throughout a woundtreatment zone and a portion of the exudate that is collected in theindividual ones of the foam/fiber gaps is transferred to and collectedin the super absorbent material.
 2. The wound dressing, as in claim 1,wherein the individual ones of the honey-dosed areas are hexagon-shapedareas.
 3. The wound dressing, as in claim wherein the super absorbentmaterial is a medical-grade, super absorbent polymer.
 4. The wounddressing, as in claim 1, wherein the super absorbent material is amedical-grade, super absorbent powder.
 5. The wound dressing, as inclaim 1, wherein the wound dressing is further comprised of: a bacterialbarrier layer having a proximal side and a distal side wherein thenon-gap patterned side of the patterned foam/fiber composite is locatedsubstantially adjacent to the proximal side of the bacterial barrierlayer.
 6. The wound dressing, as in claim 5, wherein the bacterialbarrier layer is a medical-grade, breathable polyurethane film materialwhich has an adhesive coating substantially applied to the proximalside.
 7. The wound dressing, as in claim 5, wherein the wound dressingis further comprised of: a removable liner located substantiallyadjacent to the distal side of the bacterial barrier layer.
 8. The wounddressing, as in claim 7, wherein the removable liner is a medical gradepolyethylene.
 9. The wound dressing, as in claim 5, wherein the wounddressing is her comprised of: a removable liner located substantiallyadjacent to the proximal side of the bacterial barrier layer andsubstantially enclosing the patterned foam/fiber composite, wherein theremovable liner is a medical grade, high density polyethylene.
 10. Thewound dressing, as in claim 5, wherein the wound dressing is furthercomprised of: a gel adhesive layer wherein the gel adhesive layer islocated substantially adjacent to the foam/fiber composite and theproximal side of the bacterial barrier layer.
 11. The wound dressing, asin claim 10, wherein the gel adhesive layer is a silicone gel adhesive.12. The wound dressing, as in claim 1, wherein the patterned foam/fibercomposite structure is comprised of a thickness in a range of between0.05 mm to about 100 mm.